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Abstract 
 
Anti-virulence approaches and novel peptidomimetics for combating resistant and biofilm 
associated bacteria 
 
The misuse and overuse of antibiotics has a broad impact on the environment. Antibiotic 
resistance has become a major threat for modern medical treatment of infectious diseases. There 
are multiple mechanisms leading to antibiotic resistance such as expression of cell membrane 
efflux pumps and antibiotic-degrading enzymes. Moreover, bacterial biofilm communities are 
widely accepted as a major resistance mechanism in infection sites.  
 
Biofilms are surface-associated microbial communities consisting of microcolonies embedded in 
self-produced extracellular polymer substances (EPS). EPS can contribute to cell-cell adhesion 
and restrict antibiotic penetration. Biofilm cells show much greater resistance to stressful 
conditions than their free-living counterparts. Conventional treatment strategies could not 
eradicate biofilm-related infections, such as biofilm infections related to medical implants and 
chronic wounds. There is a need for developing anti-biofilm therapeutics. 
 
Biofilm formation is a dynamic and complicated process which requires cell surface structures 
(e.g. type IV pili), motility, chemotaxis, subpopulation differentiation, iron signaling and quorum 
sensing and so on. Targeting these mechanisms might provide alternative strategies to 
conventional antimicrobial treatment. Microbial cells inside biofilms resemble planktonic cells in 
stationary phase such as their slow growth rate. Thus development of antimicrobial compounds 
which are effective against slow growing cells might also be another useful strategy. 
 
This Ph.D. project aimed at developing effective treatment strategies against biofilms formed by 
two model organisms, Pseudomonas aeruginosa and Staphylococcus epidermidis. P.aeruginosa 
is a gram-negative opportunistic pathogen which causes a variety of severe human infections and 
diseases, including colonization of the lungs of cystic fibrosis (CF) patients and infection of 
burns and immunecompromised patients. S.epidermidis is a gram-positive nosocomial pathogen 
which frequently causes infections associated with implanted foreign materials. In this study, 
quorum-sensing interfering compounds, iron chelators and efflux pump inhibitors (EPI) have 
been used for controlling P. aeruginosa biofilms. A series of novel peptidomimetics (α-
peptide/β-peptoid chimeras) have been tested against cells from stationary growth phase and 
biofilms of S. epidermidis. Structure-activity relationship and cytotoxicity features of these 
peptidomimetics were explored. Transcriptomic, genomic and adaptive evolution approaches 
have been applied to address the potential risk of resistance of peptidomimetics, which in turn 
provide useful information for designing the next generation peptide based anti-biofilm 
compounds. 
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1 Introduction 
 
This initial chapter aims at introducing the problems caused by bacterial antibiotic resistance and 
biofilms.   
1.1 Bacterial antibiotic resistance 
 
The discovery of penicillin has initiated a period of drug innovation in the treatment of bacterial 
infectious diseases. Many types of antibiotics have been discovered based on their capability to 
either kill bacteria (bactericidal) or inhibit their growth (bacteriostatic). Figure 1 shows the 
action model of three commonly used antibiotics: ciprofloxacin, tobramycin and colistin. 
Ciprofloxacin is a fluoroquinolone and exhibits broad-spectrum antimicrobial activity by 
inhibiting the function of DNA-gyrase, which resulting in inhibition of DNA replication in 
bacteria. Tobramycin is an aminoglycoside and exhibits its antimicrobial activity by binding to 
the bacterial 30S and 50S ribosome, thus preventing protein synthesis in bacteria. The 
bactericidal colistin (also called polymyxin E) belongs to the polymyxin group of antibiotics that 
binds to lipopolysaccharides and phospholipids of the outer cell membrane of Gram-negative 
bacteria and cause membrane permeabilization. 
 
 
Figure 1.Modes of action for ciprofloxacin, tobramycin and colistin. (Drawn by Frederik and Morten) 
 
However, the high turnover rate of bacteria has made it able to evolve resistant mutants to almost 
any classes of regular antibiotics in a short time (Maki and Schuna 1978; Martinez and Baquero 
2000). 
The inappropriate usage of antibiotics has led to the emergence of antibiotic-resistant bacteria in 
modern society. Figure 2 outlines the history of antibiotic development and the rise of antibiotic 
resistance. 
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Figure 2.Schedule of antibiotic deployment and the rise of antibiotic resistance. The year each antibiotic was 
deployed is depicted above the timeline, and the year resistance to each antibiotic was observed is depicted 
below the timeline(Clatworthy, Pierson et al. 2007). 
 
Several different molecular mechanisms contribute to antibiotic resistance, including enzymatic 
deactivation of antibiotics, reduction of cell wall permeability to antibiotics, alteration of target 
sites of antibiotic, induction of efflux mechanisms to remove antibiotics (Figure 3) (Hawkey 
1998). 
 
Figure 3.Four major biochemical mechanisms of antibiotic resistance(Hawkey 1998). 
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1.2 Biofilm mediated antibiotic resistance 
 
In recent years, microbial biofilms are recognized to contribute significantly to medical 
infections and cause tremendous problems for their treatment. Biofilms are microbial matrix-
enclosed aggregations of cells adhering to biological and non-biological surfaces (Hoyle and 
Costerton 1991; Costerton, Lewandowski et al. 1995; Hall-Stoodley, Costerton et al. 2004). 
Bacteria grown in biofilms can become 10 -1,000 times more resistant to antimicrobial agents 
than their planktonic counterparts(Hoyle and Costerton 1991).Biofilms are proposed to be 
responsible for 65% of all bacterial infections (Potera 1999). Figure 4 shows biofilms formed by 
P. aeruginosa from a scratch sample of airway surface taken from a patient with persistent 
Pseudomonas infection (Kobayashi 2001).  
 
Figure 4.Biofilm formed from P. aeruginosa. A: scratch sample of airway surface taken from a patient with 
persistent Pseudomonas infection. B: Sputum from exacerbated infection showing planktonic bacteria released 
from a piece of biofilm(Kobayashi 2001).  
 
There are numerous mechanisms underlying biofilm-associated antibiotic resistance. The EPS 
materials can efficiently reduce the diffusion of antimicrobial agent to the deeper part of biofilms 
(Gulot, Georges et al. 2002). Subpopulations can be differentiated during biofilm growth which 
have distinct physiology and confer tolerance towards different classes of antibiotics (Pamp, 
Gjermansen et al. 2008). Persistent cells are frequently found in antibiotic treated biofilms which 
can spread and form new biofilms (Pamp, Gjermansen et al. 2008). Thus, a better understanding 
of biofilm physiology can facilitate development of anti-biofilm strategies. 
 
 
A B
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1.2.1 Genetic regulation of biofilm formation 
 
The formation of a heterogeneous biofilm structure is a dynamic process which requires the 
expression of different gene products (Sauer, Camper et al. 2002; Stoodley, Sauer et al. 2002; 
Klausen, Aaes-Jorgensen et al. 2003) There are many different mechanisms that contribute to 
biofilm development (Figure 5). For example, Davey et al. reported that rhamnolipid surfactant 
production may be able to maintain open channels and affect architecture in P.aeruginosa 
biofilm (Davey, Caiazza et al. 2003). Klausen et al. showed that twitching ability could 
determine the mature biofilm structure by forming the motile and non-motile subpopulations 
(Klausen, Heydorn et al. 2003). Greenberg’s group proved that iron signaling is required for the 
formation of mushroom-like biofilm structures (Banin, Vasil et al. 2005). 
 
Figure 5 outlines the development of the P. aeruginosa biofilm. The biofilm formation of this 
organism is characterized as five stages of development: (i) reversible attachment, (ii) 
irreversible attachment, (iii) maturation-1, (iv) maturation-2, and (v) dispersion(Sauer, Camper et 
al. 2002). 
 
Figure 5.Diagram showing the development of a biofilm as a five-stage process. Stage 1: initial attachment of 
cells to the surface. Stage 2: production of EPS resulting in more firmly adhered “irreversible” attachment. 
Stage 3: early development of biofilm architecture. Stage 4: maturation of biofilm architecture. Stage 5: 
dispersion of single cells from the biofilm. The bottom panels (a-e) show each of the five stages of 
development represented by a photomicrograph of P. aeruginosa when grown under continuous-flow 
conditions on a glass substratum.(Stoodley, Sauer et al. 2002) 
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1.2.2 Biofilm model organism – Pseudomonas aeruginosa 
 
P. aeruginosa is a ubiquitous Gram-negative bacterium responsible for frequent nosocomial and 
burn infections (Lyczak, Cannon et al. 2000). It is also the most frequent cause of pulmonary 
infection in patients suffering from cystic fibrosis (CF) (Deretic, Schurr et al. 1995). The chronic 
CF infection is impossible to eradicate and can ultimately lead to pulmonary failure and death 
(Frederiksen, Koch et al. 1997) (Hoiby and Koch 1990). It is hard to control P. aeruginosa 
infections because it is naturally resistant to many antibiotics. One more important reason is its 
tendency to colonize surfaces in a biofilm form which makes the cells impervious to therapeutic 
concentrations of antibiotics (Hill, Rose et al. 2005).  
Biofilm formation by P. aeruginosa requires surface pili, flagellum, extracellular 
polysaccharides, extracellular DNA (eDNA) and surface proteins (Harmsen, Yang et al. 2010). 
These components are crucial for the initial attachment of P. aeruginosa to surface. 
P. aeruginosa type IV piliare thin polar filaments 50-60 Å in diameter and up to ≈ 5 μm long. 
Type IV pili are dynamic filaments that can be extended and retracted independently of each 
other from the pole (Skerker and Berg 2001). Pili are able to attach via the tip to abiotic and 
biotic surfaces. The extension and retraction of type IV pili are the driving force of the surface-
associated so-called twitching motility (Skerker and Berg 2001). P. aeruginosa is able to swim in 
liquid by means of a single polar flagellum. Using the microtiter plate assay, O’toole and Kolter 
showed that flagella or flagellum-driven motility is required for biofilm formation by P. 
aeruginosa PA14(O'Toole and Kolter 1998). It was speculated that in static cultures, the 
swimming motility might enable the bacteria to overcome repulsive forces at the surface and that 
the microcolonies may be formed by twitching motility-driven cell aggregation.  
P. aeruginosais known to produce at least three secreted polysaccharides: Pel, Psl and alginate 
(Figure 6). These polysaccharides differ in chemical structure and biosynthetic mechanisms 
(Friedman and Kolter 2004; Stapper, Narasimhan et al. 2004; Ryder, Byrd et al. 2007). Figure 6 
shows the alginate, Psl and Pel polysaccharides in P. aeruginosa biofilms revealed by using 
Atomic Force Microscopy (AFM), Confocal laser scanning microscopy (CLSM) and Scanning 
Electron Microscopy (SEM) respectively (Franklin, Nivens et al. 2011). 
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Figure 6.Extracellular polysaccharidealginate (A), Psl (B) and Pel (C) of P. aeruginosa, visualized using three 
approaches. (A) Atomic Force Microscopy image of P.aeruginosa FRD1, showing alginate as a soft loosely 
adhered polymer that surrounds the cells. (B) Confocal laser scanning microscopy (CLSM) image of hydrated 
P. aeruginosa PAO1, cultured as a pellicle. The CLSM image shows a three-dimensional reconstruction of the 
pellicle, with the P. aeruginosa cells expressing the green fluorescent protein and the Psl polysaccharide 
counterstained with Cell Mask Orange (Invitrogen Corp.). (C) Scanning Electron Microscopy (SEM) image of 
P. aeruginosa PA14, cultured as a pellicle. The image shows the extracellular matrix, which includes Pel, as a 
fabric-like matrix that surrounds and connects the cells that form a microbial mat at the air-water interface 
(Franklin, Nivens et al. 2011). 
 
1.2.3 Biofilm model organism – Staphylococcus epidermidis 
Staphylococcus epidermidis is a Gram-positive, coagulase-negative cocci that belongs to our 
normal flora. It causes catheter-associated biofilm infections and remains an important cause of 
nosocomial infection (Donlan 2001).  
 
Biofilm formation by S.epidermidis is proposed to be a four-step process involving initial 
attachment, accumulation, maturation, and detachment by Otto (Otto 2004). Several EPS 
components are required for the attachment and accumulation phases and are noted on the 
bottom of the Figure 7. The polysaccharide intercellular adhesin (PIA) is one of the most 
important EPS component involved in S.epidermidis biofilm accumulation(Mack, Fischer et al. 
1996). PIA is a linear beta-1,6-linked glucosaminoglycan which can also protect S. epidermidis 
against major components of human innate host defense, such as antimicrobial peptides(Vuong, 
Voyich et al. 2004). 
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Figure 7.Model of biofilm formation on a catheter surface in Staphylococcus epidermidis.(Otto 2004) 
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2. Anti-virulence targets and approaches 
 
The emergence of antibiotic resistance and biofilm-associated implant infections cause many 
problems for the current medical treatment for bacterial infection diseases (Costerton, Stewart et 
al. 1999). We are now entering the post-antibiotic era, with limited treatment options for many 
bacterial infections, such as the now widely disseminated multidrug-resistant P. aeruginosa and 
methicillin-resistant Staphylococcus aureus (MRSA). Thus, many alternative treatment strategies 
are currently being investigated that are based on the inhibition of bacterial virulence rather than 
of bacterial growth. Such strategies might reduce the selection pressure for antibiotic resistance 
since virulence traits are not essential for bacterial survival. Table 1 shows examples of some 
reported anti-virulence strategies, including inhibiting toxin function, toxin delivery, virulence 
expression regulator (quorum sensing), and adhesion. 
Table 1. Some of the strategies that target various pathways related to virulence (Clatworthy, Pierson et al. 
2007) 
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2.1 Efflux pump inhibitor 
 
Most bacteria have a series of efflux pump systems which are involved in the extrusion of 
substrates from within cells into the external environment (Webber and Piddock 2003). So far, 
several different families of efflux pump systems are present in bacteria, including SMR (small 
multidrug resistance), RND (resistance-nodulation-division), MFS (major facilitator 
superfamily) and ABC (ATP binding cassette) (Figure 8). The SMR, RND and MFS efflux 
systems use the proton motive force as an energy source, while the ABC efflux system utilizes 
ATP hydrolysis to drive the export of substrates(Van Bambeke, Balzi et al. 2000). 
 
Figure 8.Main classes of efflux pumps acting on antibiotics (Van Bambeke, Balzi et al. 2000). 
 
Many efflux pumps are activated only after exposure of bacterial cells to toxic substrates such as 
antibiotics (Aendekerk, Ghysels et al. 2002). Long term exposure of bacterial cells to antibiotics 
can often lead to multiple drug resistant (MDR) bacteria which consistently express certain 
efflux pumps (Poole 2000).  
 
Besides extrusion of antibiotics, some of the signal molecules which are involved in bacterial 
virulence as well as biofilm formation also require an active efflux pump system. In 
Burkholderia pseudomallei BpeAB-OprB efflux pump is required for optimal production of 
quorum-sensing-controlled virulence factors such as siderophore and phospholipase C as well as 
for biofilm formation(Chan and Chua 2005).Thus, targeting efflux pumps using efflux pump 
inhibitors (EPI) might be a potential strategy to control multiple drug resistant bacteria. A wide 
range of EPIs have been identified in recent years (Figure 9) (Pages and Amaral 2009). EPIs 
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have been shown to reduce antibiotic resistance, quorum sensing, virulence and biofilm 
formation (Hannula and Hanninen 2008; Kvist, Hancock et al. 2008; Varga, Armada et al. 2012). 
 
 
Figure 9.Some of the well-described inhibitors targeting the Gram-negative bacteria efflux pumps (Pages and 
Amaral 2009). 
 
2.2 Iron chelator 
 
Iron source is limited under both environmental conditions and host. Bacteria have evolved 
multiple iron acquisition systems to scavenge iron from minerals as well as host iron storage 
proteins (such as hemoglobin) (Wandersman and Delepelaire 2004). 
 
One of the most common mechanisms for bacterial iron acquisition is release of small, high-
affinity iron chelating compound-siderophores (Bagg and Neilands 1987). Siderophores are the 
strongest binders to Fe3+in nature and usually form a stable, hexadentate, octahedral complex 
with Fe3+. Bacteria synthesize siderophores and release them through ABC efflux systems. After 
binding with Fe3+, siderophores can be recognized by their specific receptors at the membrane 
and transported into cells (Figure 10). 
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Figure 10. Iron acquisition systems of Gram-positive and Gram-negative species (Wandersman and 
Delepelaire 2004). 
 
Iron signalling plays an important role in bacterial virulence and biofilm formation. In addition 
to its role as an iron-scavenger, the major P. aeruginosa siderophore pyoverdine regulates the 
production of several virulence factors which are major contributors to infection (Lamont, Beare 
et al. 2002). Pyoverdine also contributes to subpopulation interactions and structure development 
of P. aeruginosa biofilms (Yang, Nilsson et al. 2009). 
 
Interference of iron uptake can be used to combat bacterial infections. Lactoferrin was shown to 
repress P. aeruginosa biofilm formation by enhancing twitching motility and inhibiting micro-
colony formation (Singh, Parsek et al. 2002). Iron chelator deferoxamine and deferasirox were 
reported to enhance the activity of tobramycin against P. aeruginosa biofilm cells (Moreau-
Marquis, O'Toole et al. 2009). Siderophore-antibiotic conjugates are shown to effectively inhibit 
bacterial growth (Miller, McKee et al. 1991; Kline, Fromhold et al. 2000). 
 
2.3 Quorum sensing inhibitor 
 
It has been known that a wide range of extracellular products are regulated in a cell density-
dependent manner via cell-to-cell communication or ‘quorum sensing’ in bacteria (Miller and 
Bassler 2001). Bacteria secrete small molecules such as oligopeptides for Gram-positive bacteria 
and N-Acyl Homoserine Lactones (AHL) for Gram-negative bacteria as signaling molecules. P. 
aeruginosa possesses two AHL-dependent quorum sensing systems. These are termed the las 
and rhl systems, comprising of the LuxRI homologues, LasRI and RhlRI respectively (Swift, 
Downie et al. 2001). LasI directs the synthesis of primarily N- (3-oxododecanoyl)-L - 
homoserine lactone (3-oxo-C12-HSL) and together with the transcriptional regulator LasR 
regulates the production of virulence factors including elastase, the LasA protease, alkaline 
protease and exotoxin A (Pearson, Pesci et al. 1997). RhlI directs the synthesis of N- butanoyl- L 
-homoserine lactone (C4-HSL) which activates RhlR and in turn RhlR/C4-HSL induces the 
production of rhamnolipid, elastase, LasA protease, hydrogen cyanide, pyocyanin, siderophores 
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and the cytotoxic lectins PA-I and PA-II (Toder, Gambello et al. 1991). The las and the rhl 
systems are considered to be organized in a hierarchical manner such that the las system exerts 
transcriptional control over both rhlR and rhlI(Latifi, Foglino et al. 1996).The regulation of the P. 
aeruginosa quorum sensing network could be shown in Figure 11 (Welch, Mikkelsen et al. 
2005).  
 
 
Figure 11.The quorum sensing network in P. aeruginosa (Welch, Mikkelsen et al. 2005). 
 
It has been found that quorum sensing regulated genes are involved in biofilm maturation and 
survival. A PAO1 lasI mutant defective in quorum sensing signal OdDHL production was unable 
to structurally mature into mushroom shaped SDS-resistant microcolonies as in the wild type but 
developed a flat SDS-susceptible biofilm (Davies, Parsek et al. 1998). Another study found that 
arhlI mutant formed pillar like structures compared to more mushroom shaped wilt type structure 
(Lequette and Greenberg 2005). The quorum sensing double mutant lasRrhlR showed a similar 
pattern of changes in formation of looser biofilm structures as well as increased sensitivity to 
antimicrobial factors tobramycin, hydrogen peroxide and polymorphonuclear leukocytes (PMN) 
(Figure 12) (Bjarnsholt, Jensen et al. 2005).  
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Figure 12.Tobramycin treatment of P. aeruginosa biofilms. Wild type P. aeruginosa and the lasRrhlR mutant, 
both expressing GFP as a tag, were grown as biofilms in flow chambers for 3 days. On day 3, 10 mg 
tobramycin ml-1 or 20 mg tobramycin ml-1 was added to the biofilm flow medium. Propidium iodide was 
added to the media after day 3 to continuously monitor the killing of the tobramycin-treated biofilms and the 
control. The present pictures show biofilms after 48 h of tobramycin treatment. (a) Untreated wild type; (b) 10 
mg tobramycin ml-1, wild type; (c) 20 mg tobramycin ml-1, wild type; (d) untreated lasRrhlR; (e) 10 mg 
tobramycin ml-1, lasRrhlR; (f) 20 mg tobramycin ml-1, lasRrhlR.(Bjarnsholt, Jensen et al. 2005) 
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3 Peptidomimetics 
 
Antimicrobial peptides (AMPs) have been considered an alternative to conventional antibiotics, 
due to their rapid-action, broad antimicrobial activity, immunomodulatory capability, and 
potency against slow-growing cells and biofilm cells. However, the application of natural AMPs 
has been limited by some properties, such as protease susceptibility, intrinsic toxicity, and high 
cost of production. Therefore, great efforts have been made on the de novo design of synthetic 
mimics of antimicrobial peptides (peptidomimetics) with high therapeutic potential and low 
clinical setbacks. 
In order to facilitate the rational design of novel peptidomimetics, it is necessary to better 
understand the features, structure–activity relationships and the mechanisms of resistance 
development of AMPs. In addition, efforts should be spent on structure optimization and mode-
of action study of peptidomimetics. 
 
3.1 Antimicrobial peptides 
 
Several hundreds of AMPs have been identified from almost all living organisms such as 
bacteria, fungi, plants, invertebrate and vertebrates species (Hancock and Chapple 1999).AMPs 
play an important role in our innate immune system for elimination of invading pathogenic 
microorganisms, including Gram-positive and Gram-negative bacteria, fungi, and 
viruses(Hancock 2001; Brown and Hancock 2006; Hancock and Sahl 2006; Diamond, Beckloff 
et al. 2009). AMPs can directly kill microbial cells by damaging their cell envelopes. They can 
also recruit and promote other elements of innate immune response in higher organisms (Scott 
and Hancock 2000; Yang, Biragyn et al. 2004; Bowdish, Davidson et al. 2005; Hancock and 
Sahl 2006)(Figure 13). Regarding their functions and features, they have generally been termed 
‘cationic antimicrobial peptides’, ‘host-defense peptides’, or ‘cationic amphiphilic peptides’.For 
clarity, the term cationic antimicrobial peptides, abbreviated to AMPs, is used in this thesis. 
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Figure 13.Biological function of host defense AMPs. Both direct antimicrobial killing and innate immune 
modulation occur with such peptides although certain peptides have one or the other activity preferentially. 
(Hancock and Sahl 2006) 
 
3.1.1 Natural properties of AMPs 
 
Individual AMPs are extremely diverse in their primary sequences and have a wide range of 
secondary structures. The four most prominent structures include α-helices, β-sheets (stabilized 
by two or three disulphide bonds), looped structures (due to a single disulphide bond) and 
extended structures rich in certain amino acids. The β-sheet and α-helical molecules are by far 
the most common AMPs in nature. Somemajor structural classes and examples of AMPs are 
showed in Figure 14.Such asα-helical magainin-2, β-sheeted polyphemusin, extended 
indolicidin, looped thanatin, and human β-defensin-2 of mixed structure (Hancock 2001; 
Hancock and Sahl 2006). 
 
Despite the various primary sequences and different secondary structures, AMPs show similar 
general physical features. They are normally short (12-50 amino acids), positively charged (net 
charge of +2 to +9), and fold into amphiphilic secondary structures upon binding to 
biomembranes. They often contain the basic amino acids lysine orarginine, giving a net positive 
charge, anda substantial proportion (≈50%) of the hydrophobic residues alanine, leucine, 
phenylalanineor tryptophan (Hancock 2001; Hancock and Sahl 2006).  
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Figure 14. Major structural classes of antimicrobial peptides.(A) Mixed structure of human β-defensin-2 (PDB 
code 1FQQ) (216); (B) looped thanatin (PDB code 8TFV); (C) β -sheeted polyphemusin (PDB code 1RKK) 
(202);(D) rabbit kidney defensin-1 (PDB code 1EWS) (165);(E) α -helical magainin-2 (PDB code 2MAG) 
(76); (F) extended indolicidin (PDB code 1G89) (212). The disulfide bonds are indicated in yellow.(Jenssen, 
Hamill et al. 2006) 
 
3.1.2 Mode of action of antimicrobial peptides 
 
The most important features of AMPs concerning their activity are their positive charge and 
amphiphilicity. The overall positive charge ensures accumulation at negatively charged 
microbial cell surfaces that contain acidicpolymers, such as lipopolysaccharide(LPS), and wall-
associated teichoic acids, of Gram-negative and Gram-positive bacteria respectively. Owing to 
the presence of disulphide bridges or interaction with target membranes, nearly all AMPs fold 
into amphiphilic structures. The positively charged polar face helps the peptide to reach the 
target membrane through electrostatic bonding, and the nonpolar face of the peptides allows 
insertion into the lipid bilayer through hydrophobic interactions (Powers and Hancock 2003; 
Yeaman and Yount 2003). 
 
After insertion into the membrane, antimicrobial peptides act by either disrupting the physical 
integrity of the membrane, or translocation across the membrane and act on internal targets, 
mediate cell killing by inhibition of nucleic acid synthesis, protein synthesis, enzymatic activity, 
or cell wall synthesis(Brogden 2005; Jenssen, Hamill et al. 2006)(Figure 15).  
Four models have been proposed for the membrane disruption mechanisms of AMPs. In the first 
model, peptides reorient to span the membrane as an aggregate with micelle-like complexes of 
peptides and lipids, but without adopting any particular orientation (Figure 15A). In the second 
and third models, peptide molecules are inserted into the membrane, forming either toroidal pore 
(Figure 15B) or barrel-stave channels (Figure 15C). For the fourth model, peptides cover the 
membrane surface in a carpet-like manner, act through the detergent-like dissolution of 
membrane, and subsequently leading to membrane disruption (Figure 15D). 
 
Indeed, besides the membrane disruption mechanism, AMPs have been shown to have 
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alternative ways of causing cell death. Some may interact with internal anionic targets such as 
nucleic acids, cellular enzymes. For example, buforin II, pleurocidin, and dermaseptin have all 
been shown to penetrate the cell membrane and inhibit DNA and RNA synthesis (Park, Kim et al. 
1998; Patrzykat, Friedrich et al. 2002; Rotem and Mor 2009) (Figure 15E). Some AMPs can 
interfere with protein synthesis, folding or function. For instance, indolicidin and the pig 
cathelicidin PR-39 can reduce the rate of protein synthesis in target bacterial cells (Boman, 
Agerberth et al. 1993; Sitaram, Subbalakshmi et al. 2003) (Figure 15F). The insect antimicrobial 
peptides pyrrhocoricin, drosocin and apidaecin have been shown to inhibit correct folding of 
proteins by targeting the bacterial chaperone DnaK (Otvos, O et al. 2000; Kragol, Lovas et al. 
2001) (Figure 15G). Some AMPs can specifically inhibit the activity of aminoglycoside-
modifying enzymes, which contain an anionic binding pocket (Boehr, Draker et al. 2003) 
(Figure 15H). Some AMPs can also target the formation of cell wall structure (Figure 15I). For 
instance, lantibiotics such as nisin and mersacidin can interfere with the transglycosylation of 
lipid II, which is necessary for the synthesis of peptidoglycan (Brotz, Bierbaum et al. 1997; 
Brumfitt, Salton et al. 2002; Kruszewska, Sahl et al. 2004). 
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Figure 15.Mechanisms of action of antimicrobial peptides. The bacterial membrane is represented as a yellow 
lipid bilayer with the peptides shown as cylinders, where the hydrophilic regions are colored red and the 
hydrophobic regions are blue. Cell wall-associated peptidoglycan molecules are depicted as purple cylinders. 
Models to explain mechanisms of membrane permeabilization are “aggregate” model (A), “toroidal pore” 
model (B), “barrel-stave” model (C), and “carpet” model (D). The mechanisms of action of peptides which do 
not act by permeabilizing the bacterial membrane are depicted in panels (E) inhibition of DNA and RNA 
synthesis; (F) decrease the rate of protein synthesis; (G)  inhibition of correct protein folding;  (H) inhibition of 
enzymes involved in the modification of aminoglycosides; (I) interfere with cell wall synthesis. (Jenssen, 
Hamill et al. 2006) 
 
3.1.3 AMPs as antibiotics (advantages and limits) 
 
Due to their distinct bactericidal activity, APMs have been in now used to treat infections caused 
by multidrug resistant bacteria. For example, colistin, a polymyxin class of AMP, was used for 
the treatment of infections caused by multidrug-resistant (MDR) gram-negative bacteria such as 
P. aeruginosa and Acinetobacter baumannii (Falagas and Kasiakou 2005).  
 
The activities of many conventional antibiotics are often hindered by slow growing cells with 
low level of metabolic rate (Brown, Allison et al. 1988). In contrast, AMPs effectively kill slow 
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growing microbial cells such as cells from biofilms (Batoni, Maisetta et al. 2011). Thus, a 
combination of AMPs and conventional antibiotics has been recently shown to be a feasible 
strategy to treat biofilms both in vitro and in vivo. Figure 16 shows that colistin-tobramycin 
combinations are better at killing of biofilm P. aeruginosa than their single usage (Herrmann, 
Yang et al. 2010). 
 
 
Figure 16.Distribution of live (green) and dead(red) cells in Pseudomonas aeruginosa biofilms. Biofilms were 
grown in laminar flow for 4 days and then were continuously exposed to 10 x minimum inhibitory 
concentrations of colistin, tobramycin, and the combination of colistin sulphate and tobramycin for 24 h(A–C) 
(Herrmann, Yang et al. 2010). 
 
Despite many attractive features, AMPs still have many unfavorable characteristics which 
limited their applications. Table 2summarizes both the advantages and disadvantages of AMPs 
(Gordon, Romanowski et al. 2005). 
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Table 2.Advantages and disadvantages of AMPs as antibiotics (Gordon, Romanowski et al. 2005) 
Advantages 
 Broad-spectrum activity (antibacterial, antiviral, antifungal) 
 Rapid onset of killing 
Cidal activity 
 Potentially low levels of induced resistance 
 Concomitant broad anti-inflammatory activities 
Disadvantages 
 Discovery costs of synthesis and screening 
 Patent exclusivity for economic viability 
 Systemic and local toxicity  
 Reduced activity based on salt, serum, and pH sensitivity 
 Susceptibility to proteolysis 
 Pharmacokinetic (PK) and pharmacodynamic (PD) issues 
 Sensitization and allergy after repeated application 
 Natural resistance (e.g., Serratia marcescens) 
 Confounding biological functions (e.g., angiogenesis) 
 High manufacturing costs 
 
3.2 AMPs resistance 
 
Several important pathogens such as S. aureus, S. epidermidis, Salmonella enterica, and 
Paeruginosa have evolved multiple strategies for conferring intrinsic or inducible resistance 
towards AMPs. When exposed to AMPs, those bacteria have specific sensing systems which 
activate those AMP resistance mechanisms.  
3.2.1 Bacterial mechanisms of AMP resistance 
 
The most common bacterial mechanisms of AMP resistance include modifications of the cell 
envelope, the inactivation of AMPs and active extrusion of harmful peptides. 
 
As the initial interactions between bacteria and AMPs are driven by electrostatic forces, 
resistance can be achieved by increase of the positive charge of the cell surface to repel cationic 
AMPs. As shown in Figure 17, the mechanisms are often different between Gram-positive and 
Gram-negative bacteria owing to the different composition of their cell envelope surfaces (Nizet 
2006). In Salmonella typhimurium, AMP resistance is mainly achieved by modifications of lipid 
A in the outer membrane, either by acylation (PagP) (Guo, Lim et al. 1998) or addition of an 
aminoarabinose moiety (Pmr system) (Gunn, Ryan et al. 2000). In many Gram-positive bacteria 
such as S. aureus, Streptococcus pyogenes, D-alanylation of the cell wall teichoic acids (Dlt 
operon) contributes to AMP resistance (Abachin, Poyart et al. 2002; Kristian, Datta et al. 2005). 
Another strategy exploited by S. aureus is the MprF-mediated lysinylation of the major 
membrane lipid phosphatidylglycerol, leading to the formation of positively charged 
lysylphosphatidylglycerol (LPG)(Peschel, Jack et al. 2001; Nishi, Komatsuzawa et al. 2004). 
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Figure 17.Bacterial resistance to cationic antimicrobial peptides mediated by alterations in surface 
charge.(Nizet 2006) 
 
Besides charge, other physico-chemical properties of the cell membrane also influence the 
membrane integration of AMPs. Bacterial resistance can be achieved by alteration of those 
properties. For example, it confers AMP resistance for S.aureus, by increasing membrane 
fluidity via elevated levels of longer-chain and unsaturated lipids (Bayer, Prasad et al. 2000). 
Some so-called small colony variants (SCVs) of S. aureus are more resistant to AMPs due to 
their reduced membrane potential (Yeaman and Bayer 2006).  
 
Many bacteria produce AMP-degrading proteases, such as protease V8 secreted by S. aureus and 
the protease SepA of S. epidermidis (Sieprawska-Lupa, Mydel et al. 2004; Lai, Villaruz et al. 
2007). Moreover, AMPs-trapping molecules were produced to bind or neutralize AMPs, such as 
staphylokinase secreted by S.aureus and the M1 surface protein of Group A Streptococcus (GAS) 
(Jin, Bokarewa et al. 2004; Lauth, von Kockritz-Blickwede et al. 2009). 
The extrusion of harmful AMPs by efflux pumps is another important mechanism of bacterial 
resistance against AMPs. For example, the MtrCE system of Neisseria gonorrhoeae and QacA 
of S. aureus export toxic substances out of the cell and away from the membrane by utilizing 
proton motive force (PMF)(Shafer, Qu et al. 1998; Kupferwasser, Skurray et al. 1999). The 
extrusion of lantibiotic epidermidin out from S.epidermidis cytoplasmis mediated by the EpiEFG 
ABC (ATP binding cassette) transporter (Peschel and Gotz 1996; Otto, Peschel et al. 1998). 
 
3.2.2 AMP sensing systems 
 
For the survival of bacteria it is crucial that they can sense and rapidly react to environmental 
threats. Two-component sensor/regulator systems (TCSs) play essential roles in bacteria for 
obtaining environmental information. TCSs are composed of two functional units, a membrane-
anchored sensor histidine kinase (HK) sensing extracellular signals and a cytoplasm response 
regulator (RR) mediating differential gene expression (Hoch 2000). 
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The first described AMP sensing systems are the Gram-negative PhoP/PhoQ and the Gram-
positive Aps systems which are based on investigations done in Salmonella typhimurium and 
Staphylococcus epidermidis, respectively. Both possess Two-component sensor/regulator 
systems (TCSs). Notably, the Aps system has a third component ApsX with unknown function. 
Another significant difference between the two systems is that, while the staphylococcal Aps 
system predominantly up-regulates AMP resistance mechanisms, the PhoP/PhoQ regulon 
controls various genes not necessarily limited to AMP resistance mechanisms, but apparently 
involved in abroad scale innate host defense(Otto 2009). 
 
Figure 18.The Gram-positive and Gram-negative AMP sensors respectively. A, The Staphylococcus Aps 
system. B, The Salmonella PhoP/PhoQ system. The main regulatory targets of the systems are shown at 
thebottom.(Otto 2009) 
 
Figure 18A shows the model of Aps sensor and regulated mechanisms in S.epidermidis and 
S.aureus (Li, Cha et al. 2007; Li, Lai et al. 2007; Otto 2009). ApsS is the membrane-anchored 
histidine kinase sensor part, ApsR is the cytoplasmic response regulator DNA-binding protein 
that interacts with target gene promoters, while the role of ApsX in the signaling transduction is 
unknown. Cationic AMPs bind to the anionic loop of ApsS and trigger activation of the Aps 
system, leading to activation of mechanisms involved in cationic AMP resistance:(i) D-
alanylation of teichoic acids by the dlt system, (ii) lysylination of phospholipids by MprF, and 
(iii) putative transport of AMPs through an ABC transporter (VraFG).The VraFG transporter is 
previously described to confer resistance to the glycopeptide antibiotic vancomycin. The 
transporter may work either by expelling the pore-forming peptides from the membrane or by 
importing them into the cell for proteolytic inactivation.  
The Gram-negative PhoP/PhoQ system (Figure 18B) is a intensively studied bacterial two-
component signal transduction system(Groisman 2001). Stimulants such as low concentration of 
divalent cations, low pH, and cationic AMPs, activate the PhoQ sensor, which phosphorylates 
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PhoP. The activated PhoP regulates a series of genes and cellular activities, such as modification 
of lipopolysaccharide (LPS), synthesis of AMP-degrading proteases, and also activates a further 
two-component regulatory system pmrA/pmrB, which also up-regulates genes involved in LPS 
modification and resistance to polymyxin B (Gunn and Miller 1996). Besides, the PhoP/PhoQ 
system also activates the genes of Mg2+ transport(Garcia Vescovi, Soncini et al. 1996), and 
survival in macrophages (Miller, Kukral et al. 1989).  
Importantly, besides the specific AMP resistance mechanisms, there are some general stress 
response systems which are capable of recognizing AMPs and to respond to their presenceThe 
alternative sigma (factors, which activated by adequate triggers, can alter the promoter 
selectivity of RNA polymerase, therefore regulate gene expression and only optimal sets of 
genes are transcribed under the specific conditions(Paget and Helmann 2003).For example, the 
SigW and SigM extracytoplasmic sigma factors were activated when Bacillus subtilis was 
exposed to AMPs(Pietiainen, Gardemeister et al. 2005). 
 
Finally, Table 3 summarizes the most comment AMP resistance mechanism from different 
bacteria. 
 
Table 3. Mechanisms of bacterial antimicrobial peptide resistance(Nizet 2006) 
 
AMP Resistance Phenotype  Gene(s)  
AMPs 
Affected 
Organism(s)  Selected Reference 
Cell Surface Alterations  
D-alanylation of teichoic acid 
in bacterial cell wall  
dlt operon  
Defensins, 
Caths * 
Staphylococcus aureus 
Group B Streptococcus  
(Collins, Kristian et 
al. 2002);   (Poyart, 
Pellegrini et al. 
2003) 
L-lysine to phosphatidylg-
lycerol  
mprF            
lysS 
Defensins, 
Caths  
Staphylococcus aureus  
(Peschel, Jack et al. 
2001);(Nishi, 
Komatsuzawa et al. 
2004) 
Addition of aminoarabinose to 
lipid A in LPS  
pmr genes  
Defensins, 
Caths  
Salmonella enterica 
Pseudomonas 
aeruginosa  
(Gunn, Ernst et al. 
2000); (Moskowitz, 
Ernst et al. 2004) 
Acylation of lipid A in LPS  pagP  
Defensins, 
Caths  
Salmonella enterica e  
(Guo, Lim et al. 
1998) 
Proteolytic Degradation of AMPs  
Elastase  lasB  Caths  
Pseudomonas 
aeruginosa  
(Schmidtchen, Frick 
et al. 2002) 
Metalloproteinase 
(aureolysin)  
aur  Caths  Staphylococcus aureus  
(Sieprawska-Lupa, 
Mydel et al. 2004) 
Surface protease  pgtE  Caths  Salmonella enterica  
(Guina, Yi et al. 
2000) 
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AMP Trapping Mechanisms  
Staphylokinase  sak  Defensins  Staphylococcus aureus  
(Jin, Bokarewa et al. 
2004) 
M1 surface protein  emm1  Caths  Group A Streptococcus  
(Lauth, von 
Kockritz-Blickwede 
et al. 2009) 
SIC protein  sic  
Defensins, 
Caths  
Group A Streptococcus  
(Frick, Akesson et al. 
2003) 
Shedding of host 
proteoglycans that in turn 
neutralize AMPs  
lasA  
Defensins, 
Caths  
Pseudomonas 
aeruginosa Group A 
Streptococcus  
(Park, Pier et al. 
2001; Schmidtchen, 
Frick et al. 2001) 
Active Efflux of AMPs  
ATP-dependent efflux system  mtr genes  Caths  Neisseria gonorrhoeae  
(Jerse, Sharma et al. 
2003) 
K+-linked efflux pump  
sap operon   
sapA  
Protamine 
Defensins  
Salmonella enterica 
Haemophilus 
influenzae  
(Parra-Lopez, Lin et 
al. 1994; Mason, 
Munson et al. 2005) 
Plasmid-encoded efflux pump  qacA  
Rabbit 
tPMP  
Staphylococcus aureus  
(Kupferwasser, 
Skurray et al. 1999) 
Alteration of Host Processes  
Downregulate AMP 
transcription  
Unknown  Caths  Shigella dysenteriae  
(Islam, Bandholtz et 
al. 2001) 
Stimulation of host 
cathepsins  
Unknown  Defensins  
Pseudomonas 
aeruginosa  
(Taggart, Greene et 
al. 2003) 
Regulatory Networks  
Two-component regulator  phoP/ phoQ  
Defensins, 
protamine  
Salmonella enterica 
Pseudomonas 
aeruginosa  
(Macfarlane, 
Kwasnicka et al. 
2000; Ernst, Guina 
et al. 2001) 
Two-component regulator  pmrA/ pmrB  
Defensins, 
Polymyxin 
B  
Salmonella enterica 
Pseudomonas 
aeruginosa  
(Gunn, Ryan et al. 
2000; McPhee, 
Lewenza et al. 
2003) 
Three-component regulator apsS/apsR/apsX Defensins 
S.epidermidis 
Staphylococcus aureus 
(Li, Lai et al. 2007) 
(Li, Cha et al. 2007) 
Extracytoplasmic sigma factor  rpoE  Defensins  Salmonella enterica  
(Crouch, Becker et 
al. 2005) 
Thermoregulated 
transcription factor  
prfA  Defensins  
Listeria 
monocytogenes  
(Lopez-Solanilla, 
Gonzalez-Zorn et al. 
2003) 
26 
 
* Abbreviation: Cath = cathelicidin.  
 
3.2.3 Experimental evolution of bacterial resistance towards AMP antibiotics 
Even throughout million years’ co-evolution, few bacterial species have developed highly 
resistance against AMPs (Peschel and Sahl 2006). AMPs operate through non-specific 
mechanisms, targeting the cell membranes and other macromolecules, and therefore have been 
considered to be less likely to induce bacterial resistance than conventional antibiotics(Zasloff 
2002). 
 
Experimental evolution studies have been used in the study of bacterial resistance development 
toward AMP antibiotics. The studies indicated that resistance towards some specific AMP 
antibiotics, such as pexiganan derived from magainin and a AMP mimic based on phenylene 
ethynylene (SMAMP1), was much harder to obtain than other conventional antibiotics (Perron, 
Zasloff et al. 2006; Tew, Clements et al. 2006). 
 
 
Figure 19. Susceptibility of S. aureus to develop resistance against SMAMP1, as well as two conventional 
antibiotics, ciprofloxacin and norfloxacin. Modified from(Tew, Clements et al. 2006) 
 
A more thorough understanding of the mechanisms of AMP mode of action as well as bacteria 
resistance may provide novel strategies or templates for designing novel AMP antibiotics, 
especially for prevention or treatment of infections caused by pathogens resistant to conventional 
antibiotics. 
 
3.3 Peptidomimetics and peptide-mimetic polymers 
 
To date, great efforts have been dedicated on developing AMP mimics (peptidomimetics) with 
high therapeutic potential and low clinical setbacks, either through the modification of existing 
peptides, or the de novo synthesis of structure mimics of AMPs.  
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Several strategies are used for de novo synthesis of peptidomimetics. Among which,  the peptide-
mimetic polymer approach draws broad interest due to its relatively low cost of production as 
well as the ease of tuning key structural parameters. The design principle combines the 
biological features of antimicrobial peptides and the facile and inexpensive polymer synthesis 
methods, which have led to a new class of affordable and biocompatible antimicrobials(Palermo 
and Kuroda 2010). Many kinds of peptidomimetics have been developed using this method, such 
as synthetic oligomers  (Tew, Scott et al. 2010), dendrimers (Chen, Beck-Tan et al. 2000), and 
linear polymers (Ilker, Nusslein et al. 2004; Mowery, Lee et al. 2007; Kuroda, Caputo et al. 
2009). 
 
3.3.1 Design principles of peptide-mimetic polymers 
 
The most important concerns of peptidomimetic development are the in vivo stability, intrinsic 
toxicity and suitable formulation considering the cost of production.  
Recently, several strategies have been used to design novel AMP polymers. In these systems, 
extensive optimization has led to a select few compounds that displayed potent antimicrobial 
activity combined with high protease stability and low cytotoxicity.  Despite the diversity in 
molecular size, sequence, and conformation, these lead compounds all showed potential activity. 
Interestingly, promising antimicrobial efficacy of α/β-peptides was achieved even when the 
peptides were not able to form amphiphilic helices (Schmitt, Weisblum et al. 2004).This 
indicates that the activity of AMP polymers seems to depend on their physiochemical properties 
or global properties of polymer chains instead of defined sequence and secondary 
structure(Palermo and Kuroda 2010). 
The principle of designing peptide-mimetic polymers is to achieve better properties while 
retaining the basic properties of membrane-active natural AMPs such as positive charge and 
amphiphilicity. In addition, the length (molecular weight) is optimized to avoid hemolysis and 
retain antimicrobial activity (Table 3). 
 
Table 3 Design principles which enable favorable activity profiles in peptide-mimetic polymers(Palermo and 
Kuroda 2010) 
 
Parameter  Rationale  Design strategies  References 
Amphiphilic  
balance  
Cationic groups confer selectivity  Random copolymers (fHB ∼0.4)  (Kuroda, Caputo et al. 
2009);  
(Mowery, Lee et al. 2007) 
Tune hydrophobicity for non-hemolytic,  
antimicrobial activity  
Amphiphilic homopolymers  (Ilker, Nusslein et al. 2004); 
(Lienkamp, Madkour et al. 
2008) 
PEGylated polymer disinfectants  (Sellenet, Allison et al. 2007) 
Type of cationic  
groups  
Cationic groups with high affinity and  
selectivity for bacterial membranes  
Primary amines  (Palermo and Kuroda 2009) 
Guanidine  (Gabriel, Madkour et al. 
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2008) 
Quaternized pyridines with  
“same center” arrangement  
(Sellenet, Allison et al. 2007; 
Sambhy, Peterson et al. 
2008) 
Typeof 
hydrophobic  
groups  
Minimize overall hydrophobicity  
to avoid hemolytic activity  
Short alkyl (methyl, ethyl)  (Kuroda, Caputo et al. 
2009);  
(Lienkamp, Madkour et al. 
2008) 
Cyclic groups (cyclohexene)  (Mowery, Lee et al. 2007) 
MW  Optimal length to avoid hemolysis  
and retain antimicrobial activity  
<10 kDa for low hemolysis  
and antimicrobial potency  
(Kuroda and DeGrado 
2005); (Mowery, Lindner et 
al. 2009) 
 
 
3.3.2 α-peptide/β-peptoid chimeras 
 
Several approaches are employed in designing AMP mimicry: Incorporation of unnatural α-
amino acids, partial or complete replacement of α-amino acids with β-amino acids (Cheng, 
Gellman et al. 2001; Seebach, Beck et al. 2004)or oligomers of N-alkylglycines (i.e,. α-
peptoids)(Zuckermann, Kerr et al. 1992)(Figure 21). 
Peptoids (N-alkylated oligoglycines) are isomers of peptides, with the side chains attached to the 
backbone nitrogen rather than to the α–carbon(Simon, Kania et al. 1992). Peptoids are 
extensively used for achieving AMP mimicry, since they are easily synthesized on solid phase 
with diverse sequences at relatively low cost(Zuckermann, Kerr et al. 1992). 
 
 
Figure 21. Backbone structures of natural R-peptides and mainpeptidomimetic designs (peptoid)(Zuckermann, 
Kerr et al. 1992). 
 
Indeed, the protease-resistant compounds β-peptides (Porter, Wang et al. 2000; Arvidsson, Ryder 
et al. 2005) and peptoids (Chongsiriwatana, Patch et al. 2008)are being intensively investigated 
as antibacterials.  
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Also, oligomers composed of two different types of residues are capable of imitating the 
antibiotic activity of natural AMPs (Schmitt, Weisblum et al. 2007; Horne and Gellman 2008). 
An approach for the design and synthesis of a series of α-peptide/β-peptoid chimeras has been 
reported previously. This kind of peptidomimetics consists of alternating repeats of α-peptide 
and β-peptoid residues. In this design, lysine (Lys) and/or homoarginine (hArg) contribute to 
strongly cationic properties and intramolecular hydrogen-bonding capacity, while β-peptoid 
residues seem to improve lipophilicity, structure-promoting effects, and protease resistance 
(Foged, Franzyk et al. 2008). They were synthesized using standard solid-phase procedures, and 
the method is suitable for large-scale, cost-efficient manufacturing(Olsen, Bonke et al. 2007; 
Olsen, Ziegler et al. 2010; Hein-Kristensen, Knapp et al. 2011).These chimeras exhibit a broad 
spectrum of activities being potent against several Gram-negative bacteria, Gram-positive 
bacteria, fungi, and parasites. In addition, they are non-hemolytic and highly resistant to 
degradation by proteases (Olsen, Bonke et al. 2007; Olsen, Lambert et al. 2008; Olsen, Ziegler et 
al. 2010). 
 
Figure 22.Chemical structures of the α-peptide/β-peptoid hybrid oligomers. The abbreviations used for the β-
peptoid units were adapted from the abbreviations commonly used for peptoids (i.e., N-alkylglycines), by 
adding the β-prefix. βNspe=N-(S)-1-phenylethyl-balanine, βNphe=β-N-phenylalanine, hArg=homoarginine. 
 
Some structure-activity relationship (SAR) studies have been performed. Circular dichroism (CD) 
spectroscopy demonstrates the presence of some degree of secondary structure(Olsen, Bonke et 
al. 2007; Olsen, Lambert et al. 2008; Olsen, Ziegler et al. 2010).Notably, a higher degree of 
secondary structure was found for analogues containing chiral side chains in the β-peptoid units 
as compared to chimeras with achiral β-peptoid residues (Olsen, Bonke et al. 2007), but the 
effect of this on antibacterial activity remains largely unresolved (Olsen, Ziegler et al. 2010). 
The membrane-destabilizing effects of the chimeras have been investigated in model liposomes 
prepared from phosphatidylcholine, and several of the chimeras permeabilized such liposomal 
membranes (Foged, Franzyk et al. 2008). In addition, the effects of some of the chimeras on cell 
membranes of viable bacteria and the effects of membrane permeabilization on killing of 
bacteria were tested. The synthetic chimeras exert their killing effect by permeabilization of the 
bacterial cell envelope. The chain length of the chimeras largely influences the antibacterial 
activity. The outer membrane of Gram-negative bacteria may act as a barrier against chimeras. 
The tolerance of S. marcescens to chimeras may be owing to differences in the composition of 
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the lipopolysaccharide (LPS) layer also responsible for its resistance to polymyxin B (Hein-
Kristensen, Knapp et al. 2011).  
Efforts should be conducted to obtain intensive SAR and cytotoxicity data. Furthermore, the 
mode of action, the bacterial resistance mechanisms, and the effects of these chimeras on biofilm 
culture should be explored. This information will help us to derive useful trends for the future 
design of antimicrobial peptidomimetic constructs with potential for enhanced selectivity. 
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Concluding remarks 
 
Antibiotic resistance caused by multidrug resistant bacteria remains a major threat to our health. 
We are gradually entering into the Post-Antibiotic Era, when antibiotics no longer work. 
Meanwhile, more and more medical implants are used in hospitals which are often colonized by 
biofilm-forming bacteria such as S. epidermidis. In this thesis’ work, different approaches were 
used to combat biofilms formed by P. aeruginosa and S. epidermidis. 
 
Firstly, we targeted quorum sensing signaling pathways of P. aeruginosa. We have used 
molecular dynamics simulation and experimental studies to elucidate the efficiencies of two 
potential quorum-quenching reagents, triclosan and green tea epigallocatechin gallate (EGCG), 
which both function as inhibitors of the enoyl-acyl carrier protein (ACP) reductase (ENR) from 
the bacterial type II fatty acid synthesis pathway. Our studies suggest that EGCG has a higher 
binding affinity towards ENR of P. aeruginosa and is an efficient quorum-quenching reagent. 
EGCG treatment was further shown to be able to attenuate the production of virulence factors 
and biofilm resistance of P. aeruginosa(paper I).  
 
Secondly, we interfered with the iron signaling pathway of P. aeruginosa. The efflux pump 
inhibitor phenyl-arginine-β-naphthylamide (PAβN) was paired with iron chelators 2,2′-
dipyridyl, acetohydroxamic acid, and EDTA to assess synergistic activities against P aeruginosa 
growth and biofilm formation. All of the tested iron chelators synergistically inhibited P. 
aeruginosa growth and biofilm formation with PAβN. PAβN-EDTA showed the most promising 
activity against P. aeruginosa growth and biofilm formation (paper II). 
 
To combat another biofilm model organisms S. epidermidis, we tested the effects of novel α-
peptide/β-peptoid chimeras against the slow growing stationary growth phase and biofilm cells. 
All tested peptidomimetics were bactericidal against both exponentially growing and stationary-
phase S. epidermidis cells with similar killing kinetics. At the Minimum Inhibitory 
Concentration (MIC) all peptidomimetics inhibited biofilm formation, while peptidomimetics at 
concentrations above MIC (80-160 µg/ml) eradicated young (6-h-old) biofilms, even higher 
concentrations were needed to eradicate mature (24-h-old) biofilms completely. Cytotoxicity 
assays showed a clear correlation between oligomer length and cell toxicity within each 
subclass of peptides, but all possessed a high differential toxicity favoring killing of bacterial 
cells. The study suggests this class of peptidomimetics may constitute promising antimicrobial 
alternatives for the prevention and treatment of MDR S. epidermidis infections. (paper III). 
 
To better understand the potential resistance mechanisms of novel α-peptide/β-peptoid chimeras, 
we used transcriptomics, adaptive evolution combined with genome sequencing to identify stress 
response and resistant development after exposure of S. epidermidis to α-peptide/β-peptoid 
chimeras. Transcriptomic profiles of S.epidermidis exposed to peptidomimetics and vancomycin 
suggests that peptidomimetics target the cell membrane in a similar but distinct mode as 
vancomycin. Comparative genomic and transcriptomic analysis of evolved resistant populations 
showed that general stress response especially the stringent response is an important mechanism 
for S. epidermidis to respond to peptidomimetics. In addition, some specific mechanisms are 
involved to the defense of peptidomiemtics, such as the VraRS and Aps sensor systems, various 
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efflux pumps and membrane modification enzymes. These results suggest that peptidomimetics 
could constitute a potential additive to conventional antibiotic treatment. In addition, this study 
addressed the potential risk of resistance development of peptidomimetics, which provided 
useful information for designing the next generation peptide based antimicrobial compounds. 
(paper IV). 
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Abstract: Pseudomonas aeruginosa is an opportunistic pathogen which is responsible for 
a wide range of infections. Production of virulence factors and biofilm formation by P. 
aeruginosa are partly regulated by cell-to-cell communication quorum-sensing systems. 
Identification of quorum-quenching reagents which block the quorum-sensing process can 
facilitate development of novel treatment strategies for P. aeruginosa infections. We have 
used molecular dynamics simulation and experimental studies to elucidate the efficiencies 
of two potential quorum-quenching reagents, triclosan and green tea epigallocatechin 
gallate (EGCG), which both function as inhibitors of the enoyl-acyl carrier protein (ACP) 
reductase (ENR) from the bacterial type II fatty acid synthesis pathway. Our studies 
suggest that EGCG has a higher binding affinity towards ENR of P. aeruginosa and is an 
efficient quorum-quenching reagent. EGCG treatment was further shown to be able to 
attenuate the production of virulence factors and biofilm formation of P. aeruginosa. 
Keywords: Pseudomonas aeruginosa; quorum-quenching; enoyl-acyl carrier protein 
reductase; molecular dynamics simulation 
 
1. Introduction 
Pseudomonas aeruginosa is an opportunistic pathogen which causes a wide range of infective 
diseases such as pulmonary infections, medical-device-related infections, urinary tract infections, 
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wound infections as well as potentially fatal cystic fibrosis lung infections [1,2]. P. aeruginosa 
produces a large number of virulence factors and is notorious for its tolerance to many antimicrobial 
agents [3,4]. Another important feature of P. aeruginosa infections is the formation of surface attached 
complex multicellular communities, often referred to as biofilms [5,6]. Biofilm cells display multiple 
phenotypes and are surrounded by resistant extracellular polymeric substance (EPS) materials [7], 
which are often major causes for persistent infections [6]. Both production of virulence factors and 
biofilm formation are partly regulated by bacterial cell-to-cell communication (quorum-sensing) 
system in P. aeruginosa [3,8,9]. 
Quorum sensing (QS) is a widespread prokaryotic intercellular communication system which is 
based on the production of extracellular signal molecules (autoinducers) in relation to cell density [10]. 
Once the autoinducers reach their critical threshod concentrations, they can adjust the conformation of 
autoinducer receptors and together they can affect the expression profiles of a large number of genes 
[10]. There are three interconnected QS systems, las, rhl and pqs systems, in P. aeruginosa [3,11,12]. 
The major signal molecules involved in las, rhl and pqs QS systems are 3-oxo-C12-HSL, C4-HSL, and 
2-heptyl-3-hydroxy-4-quinolone (PQS) respectively [12,13]. Among them, the las QS system is at the 
top of the QS hierarchy regulating the rhl and pqs QS systems [14]. 
Targeting pathways which are essential for the synthesis of QS molecules might be an approach for 
identifying quorum-quenching reagents. Recently, type II fatty acid synthesis intermediates were 
shown to be substrates for the LuxI family of autoinducer synthases [15]. The type II fatty acid 
synthesis pathway is present in most prokaryotes, plants, and several protozoans and has a different 
architectural organization from the type I fatty acid synthesis pathway of animals and human beings. In 
P. aeruginosa, mutations in the type II fatty acid synthesis fabI gene, which encodes enoyl-acyl carrier 
protein (ACP) reductase (ENR), lead to significant reduction of the 3-oxo-C12-HSL molecule of the 
las QS system [16]. High-throughput screening previously identified a large number of type II fatty 
acid synthesis inhibitors for different organisms [17]. These identified compounds have been served as 
scaffolds for structure based design of novel type II fatty acid synthesis inhibitors. Studying the effects 
of different type II fatty acid synthesis inhibitors on P. aeruginosa QS can provide valuable 
information for designing novel classes of P. aeruginosa quorum-quenching reagents. 
In this study, we compared the effects of two reported broad spectrum type II fatty acid inhibitors, 
5-chloro-2-(2,4-dichlorophenoxy)phenol (triclosan) and green tea (−)-epigallocatechin gallate 
(EGCG), on P. aeruginosa QS. These two inhibitors were reported be able to specifically bind with 
and inhibit the Escherichia coli ENR (EcENR) [18,19]. Since the complete three-dimensional structure 
of P. aeruginosa ENR (PaENR) is not available yet, we built a PaENR structure model through 
homology modeling. Then we used molecular dynamics (MD) simulations to analyze the binding 
affinities of triclosan and EGCG to PaENR. The MD results suggested that EGCG had a higher 
binding affinity to PaENR than triclosan. In agreement with the MD analysis, experiments showed that 
EGCG was a more efficient inhibitor of P. aeruginosa QS regulated virulence and biofilm formation 
than triclosan.  
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2. Results and Discussion 
The P. aeruginosa QS system is a model system for studies of the N-Acyl Homoserine Lactone 
(AHLs)-mediated QS in Gram-negative bacteria. The QS systems are widely used by pathogenic 
bacteria to coordinate expression of virulence products as well as biofilm formation, which cause a 
variety of persistent infections for human beings, animals and plants [20,21]. Recently, QS systems 
were proposed as a target for the development of anti-pathogenic drugs [22]. A number of quorum-
quenching reagents were identified based on the structure of the QS signal molecules [22]. However, 
several of the QS molecule analogs are chemically unstable or toxic for animals and human beings  
[23–25]. Thus, alternative methods are needed to search for novel classes of quorum-quenching reagents 
with different structures from the QS molecules. In this work, we investigated a novel approach to 
identify quorum-quenching reagents through targeting the type II fatty acid synthesis pathway. 
2.1. MD Simulation of Binding Affinities of Compounds to PaENR 
The structure and functions of E. coli ENR (EcENR) are well studied by many different research 
groups. EcENR has high sequence similarity to the P. aeruginosa ENR (PaENR) based on blast 
searching of PaENR sequence in the RCSB protein data bank [26]. Pairwise protein sequence 
alignment shows that the essential amino acids of EcENR which are involved in binding of NADH to 
EcENR [27] are conserved between these two ENRs: the residues in PaENR corresponding to Gly-93, 
Met-159 and Phe-203 of EcENR are Gly-95, Met-162 and Phe-206 (Figure 1). 
Figure 1. Pairwise protein sequence alignment of ENR from P. aeruginosa (PaENR) with 
ENR from E. coli (EcENR). Alignment was performed by Discovery Studio Visualizer 2.0 
(Accelrys) and conserved residues are shown in dark blue with a white background. 
 
We have used the EcENR structures to build a P. aeruginosa ENR (PaENR) model by homology 
modeling with Modeller. Then we used molecular dynamics simulation to investigate the binding 
affinities of two reported EcENR inhibitors, triclosan and EGCG, to PaENR. Since bacterial ENR 
activity is NADH dependent, and both triclosan and EGCG were reported to competitively bind with 
ENR against NADH [18,19], we also simulated the binding affinity and mode of NADH with PaENR. 
The RMSD values of all of the three systems became stable after 2.4 ns simulation (data not shown). 
After MD simulation, we examined the final structures of the PaENR-triclosan, PaENR-EGCG and 
PaENR-NADH complexes by binding score analysis and hydrogen bond interaction analysis with 
Molegro Molecular Viewer. The estimated binding scores of triclosan, EGCG and NADH to PaENR 
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were -84.9197, -157.744 and -194.123 respectively and the hydrogen bond interactions of triclosan, 
EGCG and NADH to PaENR are shown in Figure 2. Based on this analysis, triclosan has fewer 
hydrogen bond interactions with PaENR than EGCG and NADH. The hydroxyl groups from EGCG 
enable it to form several hydrogen bonds with PaENR (Figure 2B). Most of the hydrogen bond 
interactions of PaENR-triclosan, PaENR-EGCG and PaENR-NADH complexes are mediated by 
amino acid residues close to residue 95, residue 150 and residue 200 (Figure 2), which is in accordance 
with the experimental crystal structure analysis of ENRs from other species [27]. Based on the MD 
simulation analysis, EGCG has a higher binding affinity to PaENR than triclosan and this result 
suggests that EGCG may have better inhibition effects towards QS activity via interfering PaENR than 
triclosan. By employing another approach, Sharma et al. used cluster analysis to group docked 
confirmations generated through 100 independent docking runs of triclosan and EGCG against Enoyl-
ACP Reductase from Plasmodium falciparum (PfENR) [28]. Similar to our results, they reported that 
triclosan and EGCG tend to occupy different binding pockets of the PfENR. Our method using 
Molegro Molecular Viewer to calculate the binding affinities of triclosan, EGCG and NADH to 
PaENR is based on simple energy functions, which is fast but provides relatively low accuracy. 
Rigorous free energy perturbation methods after MD simulation could obtain more accurate protein–
ligand binding energy [29]. 
Figure 2. Hydrogen bond interaction analysis by Molegro Molecular Viewer. A: PaENR-
triclosan; B: PaENR-EGCG; C: PaENR-NADH. 
 
2.2. Quorum-Sensing, Virulence and Biofilm Attenuation by PaENR Inhibitors 
It was shown previously that a high binding affinity to EcENR is very critical for EcENR inhibitors 
to act as antibiotics, since the AcrAB efflux system of E. coli can efficiently pump EcENR inhibitors 
out of the cells [30]. P. aeruginosa has an efflux system highly homologous to the E. coli AcrAB 
system, which was shown to be essential for its resistance to the ENR inhibitor triclosan [16]. 
Triclosan is, however, not an efficient PaENR inhibitor, and it is actually widely used in the 
Pseudomonas isolation agar (PIA; Difco) (whose formulation contains 25 μg/mL of triclosan) to 
isolate Pseudomonas species from other bacterial species (such as E. coli). We propose here that a high 
binding affinity of compounds to PaENR is necessary for them to efficiently interfere with the P. 
aeruginosa type II fatty acid synthesis and attenuate QS signaling. 
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To test our proposal we examined the quorum-quenching capabilities of triclosan and EGCG by 
means of a quorum-quenching assay based on a lasB::gfp(ASV) translational fusion in P. aeruginosa 
wild-type PAO1 strain [31]. In this assay an unstable version of Gfp (ASV) was fused with the QS 
regulated LasB protein, by which the P. aeruginosa QS activity can be indicated by measuring green 
fluorescence per OD600 unit. As shown in Figure 3, triclosan showed a slight reduction in green 
fluorescence per OD unit, while EGCG showed significant reduction in green fluorescence per OD 
unit. Both triclosan and EGCG showed no growth inhibition of P. aeruginosa PAO1 strain under our 
tested concentrations. This suggests that EGCG is an active quorum-quenching reagent. 
Figure 3. Expression of lasB:gfp(ASV) in wild-type P. aeruginosa treated with triclosan 
(black bar) and EGCG (gray bar). Results are average values of green fluorescence divided 
by OD600 taken from a single time point measurement corresponding to maximal induction 
of the reporters in the late log phase of growth. Inhibitors were added at concentrations of  
0 µM, 1 µM, 25 µM and 250 µM. Averages and SDs of three replicates are shown. 
 
We also investigated whether attenuation of P. aeruginosa QS by EGCG might lead to reduction of 
QS regulated virulence factors and activities via measuring transcription of pqsABCDE operon and 
swarming motility of P. aeruginosa PAO1 strain.  
The pqsABCDE operon is involved in synthesis of Pseudomonas quinolone signal (PQS), which 
functions as a signal molecule as well as an iron chelator [32]. The transcription of the pqsABCDE 
operon was shown to be under stringent regulation of the las QS system [33]. In the pqsABCDE 
transcription assay, an unstable version of Gfp (ASV) was fused with a QS regulated pqsABCDE 
promoter, by which the transcription of the pqsABCDE operon can be estimated by measuring green 
fluorescence per OD unit [34]. As shown in Figure 4, transcription of the pqsABCDE operon in the P. 
aeruginosa PAO1 was reduced by EGCG in a dose dependent manner. The swarming motility is 
characterized by a coordinated translocation of a bacterial population across solid or semi-solid 
surfaces. By dropping a cell pellet on the surface of a solid agar plate, bacterial cells are able to move 
away from the initial location leading to the formation of arm-like or dendritic fractal-like patterns.  
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Figure 4. Expression of pqsA:gfp(ASV) in wild-type P. aeruginosa treated with EGCG. 
Results are average values of green fluorescence divided by OD600 taken from a single time 
point measurement corresponding to maximal induction of the reporters in the late log 
phase of growth. Inhibitors were added at concentrations of 0 µM, 1 µM, 25 µM and  
250 µM. Averages and SDs of three replicates are shown. 
 
Since it was reported that both type II fatty acid synthesis [35] and PQS regulation [36] were 
involved in production of the biosurfactant rhamnolipid, which is required for P. aeruginosa swarming 
motility, we investigated whether EGCG could attenuate swarming motility of P. aeruginosa PAO1 
strain. As expected, our results showed that swarming motility by P. aeruginosa PAO1 strain was 
reduced by EGCG in a dose dependent manner (Figure 5).  
Figure 5. Swarming motility of wild-type P. aeruginosa strain on agar plates containing 0 
µM (A), 1 µM (B), 25 µM (C) and 250 µM EGCG (D). 
 
P. aeruginosa QS and swarming motility have been shown to play important roles in antibiotic 
resistance and biofilm formation [37–39]. Thus we further investigated the effects of EGCG on P. 
aeruginosa biofilm formation and its antibiotic resistance. In order to examine the effects of EGCG on 
P. aeruginosa biofilm formation, we grew Gfp tagged P. aeruginosa PAO1 in flow-chambers irrigated 
with normal FAB medium, with or without 25 µM EGCG. After 4 days of growth, the biofilms were 
observed by confocal laser scanning microscopy (CLSM), which can acquire in-focus images from 
selected depths based on fluorescence of the samples. Biofilm images were acquired point-by-point 
and three-dimensional structures of biofilms were reconstructed using the IMARIS software package 
(Bitplane AG). The P. aeruginosa PAO1 grown in normal FAB medium without EGCG formed 
heterogeneous biofilms containing mushroom-shaped multicellular structures (Figure 6A), while P. 
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aeruginosa PAO1 grown in FAB medium with 25 µM EGCG formed biofilms displaying less spatially 
organized multicellular structures (Figure 6B). After 4 days of growth, the biofilms were treated with 
50 µg/mL ciprofloxacin for 24 hours. The dead bacteria in the biofilms were visualized by CLSM after 
staining with propidium iodide. The results showed that ciprofloxacin treatment caused killing of the 
bacteria located in the outer part of the cap-portion of the mushroom-shaped structures in 4-days-old P. 
aeruginosa PAO1 biofilms grown in normal FAB medium (Figure 6C), while ciprofloxacin treatment 
caused killing of most of bacteria in P. aeruginosa PAO1 biofilms grown in FAB medium with 25 µM 
EGCG (Figure 6D). These results are in accordance with previous studies showing that quorum-
quenching reagent treated biofilms are more sensitive to treatments by antimicrobial agents [34,40,41]. 
Figure 6. 4-days-old biofilms of Gfp-tagged wild-type grown in FAB medium without 
(A) or with 25 µM EGCG (B). Biofilms were further treated with 50 µg/ml ciprofloxacin 
for 24 h (C: biofilm grown in FAB without EGCG; D: biofilm grown in FAB with 25 µM 
EGCG), after which they were stained with propidium iodide and images were acquired 
by CLSM. Live cells appear green and dead cells appear red. 
 
3. Experimental 
3.1. Homology Modeling 
The sequence of the PaENR protein is highly homologous to the EcENR protein (sequence 
similarity = 84.0%, sequence identity = 68.8%). We have built a three-dimensional structure model of 
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PaENR based on the 1.75 Å crystal structure of EcENR (accession code: 1QSG) [42]. Homology 
modeling was performed with program Modeller 9V6 [43]. The model was assessed by VARIFY 3D 
[44,45]. Out of the few predicted iterative models, the best model having the lowest value of the 
MODELLER objective function was selected for the further analysis. The 3D structures of triclosan, 
EGCG and NADH ligands were obtained from the PDBeChem database [46]. The ligands were then 
inserted into the PaENR with Molegro Molecular Viewer v1.2.0 (http://www.molegro.com/) and saved 
as protein-ligand complexes respectively. 
3.2. Molecular Dynamics Simulations 
The molecular dynamics (MD) package Desmond 2.2 (D.E. Shaw Research & Schrödinger) and 
OPLS-AA 2005 force field [47] were used for MD simulations of the three computationally built 
PaENR-ligand complexes. Hydrogen atoms were added using the protein preparation wizard in 
Maestro 9.0 (Schrödinger). Each structure was embedded in a box of TIP3P water molecules [48] with 
the buffering distance set to 10 Å. For long range electrostatics, the smooth particle mesh Ewald 
method [49] was used along with periodic boundary conditions. By assuming normal charge states of 
ionizable groups corresponding to pH 7, sodium (Na+) and chloride (Cl¯) counter-ions at physiological 
concentration of 0.015 mol/L were added in the box in random positions to ensure the global charge 
neutrality. The starting structures were relaxed by performing minimization of the model system using 
a hybrid method of the steepest descent and the limited-memory Broyden-Fletcher-Goldfarb-Shanno 
(LBFGS) algorithms [50] with a convergence threshold for the gradient in units of 1.0 kcal Å/mol. The 
minimization was followed by equilibration dynamics at constant temperature (T 310K) and constant 
pressure (P 1 bar). 2.4 ns of production MD simulations were performed for each PaENR-ligand 
complex with an integration time step of 2 fs. The constant pressure and temperature were controlled 
via Langevin dynamics method [51]. Snapshot structures were extracted for every 0.6 ps, resulting in 
4000 structures from each trajectory. Thermodynamic properties (temperature, pressure, volume and 
energy) were monitored during MD simulations to check their convergence to stable values. Analysis 
of the trajectories was performed using the VMD 1.8.7 [52]. The hydrogen bond interactions and 
binding scores of PaENR-ligand complexes were analyzed by using Molegro Molecular Viewer. 
3.3. Bacterial Cell Based Quorum-Quenching Assay  
5-Chloro-2-(2,4-dichlorophenoxy)phenol (triclosan; ≥97.0%) and (−)-epigallocatechin gallate 
(EGCG; ≥ 97.0%) were purchased from Sigma-Aldrich. The quorum-quenching assay was carried out 
by growing the P. aeruginosa lasB::gfp (ASV) QS reporter strain [30] in a 96-well microtiter tray 
(black polystyrene; Nunc) in AB medium [53] together with 0 µM, 1 µM, 25 µM and 250 µM of 
triclosan and EGCG. The microtiter tray was incubated at 34 °C over night without shaking and then 
measured in a Wallac 1420 VICTOR3 plate reader (Perkin-Elmer, MA). The instrument was set to 
measure green fluorescent protein (Gfp) expression by means of the protein’s fluorescence at 535 nm 
upon excitation at 485 nm and the growth in the wells as the OD600.  
 
Molecules 2010, 15                    
 
 
788
3.4. Virulence Inhibition Assays  
PQS synthesis assay and swarming motility assay were used as previously reported [54] with 
modification to measure the production of QS regulated virulence factors. For the PQS synthesis assay, 
the expression of a plasmid-borne pqsA::gfp(ASV) fusion in the microtitre tray cultures of the PAO1 
wild-type grown in AB medium with 0 µM, 1 µM, 25 µM and 250 µM of EGCG was measured in the 
same manner as the above P. aeruginosa lasB::gfp QS reporter strain quorum-quenching assay. For the 
swarming motility assay, swarming plates consisted of AB minimal medium supplemented with 
glucose, casamino acids, and 0.5% Bacto agar. EGCG was mixed into the medium immediately before 
casting at concentrations of 0 µM, 1 µM, 25 µM and 250 µM. The plates were left for drying without 
lids in a fume hood for 1 h at room temperature. Five-microliter drops of overnight cultures of P. 
aeruginosa wild-type PAO1 strain were placed on the prepared plates and incubated for 18 hours at 
room temperature before pictures of each plate were taken. 
3.5. Biofilm Assay  
Biofilms were grown for 4 days in flow chambers with individual channel dimensions of  
1 × 4 × 40 mm. The flow system was assembled and prepared as described previously [55]. 
Inoculation of the system was carried out by injecting 300 µL 1:1,000 diluted over night culture of a 
Gfp tagged P. aeruginosa strain [34] into flow channel with a small syringe. After inoculation, the 
flow chambers were left upside down without flow for 1 h to allow bacterial attachment to the glass 
cover, after which medium flow was started with a Watson Marlow 205S peristaltic pump. The flow 
chambers were irrigated with medium with or without 25 µM EGCG. The mean flow velocity in the 
flow chambers was 0.2 mm s/L, corresponding to laminar flow with a Reynolds number of 0.02. The 
biofilms were grown at 30 °C. Biofilm tolerance to ciprofloxacin was assessed by irrigating 4-day-old 
flow-chamber-grown P. aeruginosa biofilms with medium containing 50 µg/mL ciprofloxacin  
(MIC = 1 µg/mL) for 24 h, followed by staining of the dead cells with propidium iodide, and CLSM 
image acquisition. All microscopy observations and image acquisitions were done with a Zeiss 
LSM510 confocal laser scanning microscope (CLSM) equipped with detectors and filter sets for 
monitoring of Gfp and propidium iodide fluorescence. Images were obtained using a 40x/1.3 objective. 
Simulated three-dimensional images and sections were generated using the IMARIS software package 
(Bitplane AG). 
4. Conclusions  
Our study suggests that the type II fatty acid synthesis pathway is an alternative target for 
development of anti-virulence drug lead compounds. Type II fatty acid synthesis pathway inhibitors 
can be used synergistically with conventional antibiotics to treat bacterial biofilm related infections. 
Our study also shows that molecular dynamics simulation can be used as a tool to predict the binding 
mode and the affinity of compounds to target proteins in a relatively accurate manner. Future work of 
screening novel type II fatty acid synthesis pathway inhibitors could be done by molecular docking 
based virtual screening followed by molecular dynamics simulations. 
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Synergistic Activities of an Efflux Pump Inhibitor and Iron Chelators
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The efflux pump inhibitor phenyl-arginine--naphthylamide (PAN) was paired with iron chelators 2,2-
dipyridyl, acetohydroxamic acid, and EDTA to assess synergistic activities against Pseudomonas aeruginosa
growth and biofilm formation. All of the tested iron chelators synergistically inhibited P. aeruginosa growth and
biofilm formation with PAN. PAN-EDTA showed the most promising activity against P. aeruginosa growth
and biofilm formation.
Pseudomonas aeruginosa is an important opportunistic
pathogen that can cause a wide range of human infections (4).
P. aeruginosa is notorious for its tolerance to antimicrobial
agents and continues to cause a serious public health problem
worldwide (1). The intrinsic multidrug resistance of P. aerugi-
nosa is due, to a large extent, to the expression of efflux pump
systems, which include MexAB-oprM, MexXY-OprM,
MexCD-OprJ, and MexEF-OprN (14). These efflux systems
are reported to promote the export of antibiotics, organic
solvents, biocides, and dyes (14). Recently, efflux pump inhib-
itors (EPIs), which specifically target the efflux activity and
pump components, have been identified and proposed as novel
agents to combat drug efflux mechanisms of pathogen (10). For
example, phenyl-arginine--naphthylamide (PAN) has been
reported to be an efficient EPI for P. aeruginosa, as it can
potentiate fluoroquinolone activity in resistant P. aeruginosa
strains (9).
Among all of the reported P. aeruginosa Mex efflux systems,
MexAB-OprM is the only system that is expressed constitu-
tively in cells grown in standard laboratory media (15). This
suggests that the export of antimicrobial agents is not the
primary function of the MexAB-OprM efflux system. The
MexAB-OprM system was identified initially by growing P.
aeruginosa in iron-depleted minimal medium containing 2,2-
dipyridyl (Dipy) (13). In that study, Poole and colleagues re-
ported that MexAB-OprM is overexpressed under severe iron
limitation conditions, suggesting that the MexAB-OprM sys-
tem plays an essential role for P. aeruginosa survival under iron
limitation conditions (13). The study thus suggests that the
combination of efflux inhibitors and iron chelators synergisti-
cally inhibits P. aeruginosa growth. In the present study, we
evaluated the synergistic activities of EPI with iron chelators
against P. aeruginosa growth and biofilm formation.
The wild-type P. aeruginosa strain PAO1 (7) and two iso-
genic mutants, pvdA (deficient in the synthesis of the iron
siderophore pyoverdine [18]) and mexAB-oprM (deficient in
the synthesis of the entire MexAB-OprM efflux pump [11])
were used in this study. Bacterial strains were cultivated in AB
minimal medium supplemented with 30 mg/liter glucose (5).
The AB minimal medium is an iron-restricted medium that
promotes the production of the iron siderophore pyoverdine in
P. aeruginosa (17). Stock solutions of 100 mg/ml Dipy (Sigma-
Aldrich) in ethanol, 100 mg/ml acetohydroxamic acid (Sigma-
Aldrich) in water, and 100 mg/ml EDTA (Sigma-Aldrich) in
water were kept at 4°C until use. A stock solution of 10 mg/ml
PAN (Sigma-Aldrich) in water was kept at 20°C until use.
The growth-inhibitory assay was performed by growing P.
aeruginosa strains in 96-well microtiter dishes. Overnight cul-
tures of P. aeruginosa strains were diluted 100 times in freshly
prepared medium containing an appropriate concentration of
PAN. Diluted cultures (100 l) were added to each well of
the 96-well microtiter dishes. Iron chelators (Dipy, acetohy-
droxamic acid, and EDTA) were added to cultures in the
96-well microtiter dishes in 2-fold dilution series. Culture
dishes were incubated at 37°C for 24 h, and the optical densi-
ties of the cultures were recorded at 600 nm using a VICTOR3
plate reader (Perkin-Elmer). The evaluation of the growth-
inhibitory effect at each drug concentration was monitored in
triplicate assays. Biofilms were cultivated as previously de-
scribed (3) by partially immersing coverslips in green fluores-
cent protein (GFP)-tagged PAO1 (17) cultures in Falcon tubes
in the presence of different compounds. The ciprofloxacin
MICs for P. aeruginosa in the absence or presence of PAN
and/or iron chelators were determined by a serial dilution
assay.
The growth of P. aeruginosa PAO1 was reduced significantly
at concentrations of more than 200 g/ml PAN and 80 g/ml
Dipy, respectively (Fig. 1, first row). We observed clear syner-
gistic effects from the combination of PAN and Dipy. A
concentration of 100 g/ml PAN significantly inhibited the
growth of PAO1 in the presence of 20 g/ml Dipy, and similar
inhibition was obtained with a combination of 50 g/ml PAN
and 40 g/ml Dipy (Fig. 1, first row).
The synergistic effects of PAN and Dipy on an mexAB-
oprM mutant also were tested. The mexAB-oprM mutant was
more sensitive than the wild-type PAO1 strain to Dipy and
PAN individually as well as to the combination of the two
(Fig. 1, second row). Dipy at 40 g/ml completely inhibited the
* Corresponding author. Mailing address: Infection Microbiology
Group, Center for Systems Microbiology, Department of Systems Bi-
ology, Building 301, Technical University of Denmark, 2800 Lyngby,
Denmark. Phone: 45 4525 2526. Fax: 45 4588 7328. E-mail: ly@bio
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growth of mexAB-oprM mutant (Fig. 1, second row) but only
partially inhibited the growth of wild-type PAO1 (Fig. 1, first
row); 200 g/ml PAN reduced the growth of the mexAB-oprM
mutant to a very low level (Fig. 1, second row), while it only
partially inhibited the growth of wild-type PAO1 (Fig. 1, first
row). It also was noticed that PAO1 in the presence of more
than 100 g/ml PAN was more sensitive to Dipy than the
mexAB-oprM mutant in the presence of no PAN (Fig. 1). This
result suggests that the synergistic activities between PAN
and Dipy is only partly associated with PAN being a MexAB-
OprM efflux pump inhibitor. We also tested whether the
MexAB-OprM efflux pump is involved in pyoverdine synthesis,
since pyoverdine can facilitate the growth of P. aeruginosa
under iron-limited conditions (12). The mexAB-oprM mutant
was found to produce normal amounts of pyoverdine, and
PAN did not reduce pyoverdine synthesis in the wild-type
PAO1 strain (data not shown). The synergistic activities be-
tween PAN and Dipy might partially be due to the ability of
PAN to affect membrane integrity when added at high con-
centrations (9).
The synergistic action by PAN and Dipy on a pvdA mutant
also was tested. As expected, the pvdA mutant is more sensitive
to the iron chelator Dipy (Fig. 1, third row) than the wild-type
PAO1 strain (Fig. 1, first row). However, the PAN and Dipy
combination inhibited the growth of the pvdA mutant in the
same manner as wild-type PAO1 (Fig. 1), which indicated that
the synergistic activities between PAN and Dipy do not de-
pend on the production of the iron siderophore pyoverdine.
In a further investigation of synergistic actions by PAN and
iron chelators, the effects of acetohydroxamic acid and EDTA
combined with PAN were tested. Weak synergistic activities
from PAN and acetohydroxamic acid added at high concen-
trations (e.g., 100 g/ml of PAN and 80 g/ml of acetohy-
droxamic acid) were observed for both P. aeruginosa PAO1
and the pvdA mutant (Fig. 2A). In contrast, EDTA added at
low concentrations (such as 2.5 g/ml) significantly reduced
the growth of P. aeruginosa PAO1 and the pvdA mutant when
combined with 50 g/ml PAN (Fig. 2B). This possibly is due
to the fact that EDTA can cause the release of protein-lipopo-
lysaccharide complexes of P. aeruginosa (16). The pvdA mutant
is more sensitive to the iron chelator acetohydroxamic acid and
EDTA than wild-type PAO1 (Fig. 2). However, combinations
of PAN, acetohydroxamic acid, and EDTA inhibited the
growth of the pvdA mutant as well as wild-type PAO1 (Fig. 2).
Since both iron uptake and efflux pump activities are re-
ported to play important roles in P. aeruginosa biofilm forma-
tion (2, 11, 17, 18), we further tested whether PAN and iron
chelators could synergistically reduce P. aeruginosa biofilm for-
mation. Biofilms of P. aeruginosa strain PAO1 were cultivated
for 24 h and analyzed by confocal laser-scanning microscopy
(CLSM). To gain statistical significance, three independent
biofilm images of each biofilm were acquired by CLSM and
then analyzed by the COMSTAT program (6). All three tested
iron chelators were found to synergistically reduce P. aerugi-
nosa biofilm formation when added in combination with PAN
(Fig. 3 and 4). However, EDTA was found to increase P.
aeruginosa biofilm formation when used alone at the tested
concentration (Fig. 3 and 4). This might be due to the fact that
EDTA can cause the release of lipopolysaccharide from the
cell wall, and the lipopolysaccharide released from the cells
might serve as matrix material for the attachment of biofilm
cells (8).
Finally, we also tested the effects of combinations of PAN
and iron chelators on the antibiotic sensitivity of P. aeruginosa.
We found that PAN increased the activity of ciprofloxacin
4-fold (MIC  0.05 g/ml, down from 0.2 g/ml) at a concen-
tration of 50 g/ml in our assay. None of the three tested iron
chelators (Dipy at a concentration of 10 g/ml, acetohydrox-
FIG. 1. Growth of P. aeruginosa wild-type PAO1, mexAB-oprM mutant, and pvdA mutant in the presence of different PAN-Dipy combinations.
The optical densities of the cultures at 600 nm (OD 600) were recorded after 0, 2, 4, 6, 8, 10, 12, and 24 h of incubation at 37°C. Each value
represents the means and standard deviations from three wells of the microtiter dishes.
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amic acid at a concentration of 80 g/ml, and EDTA at a
concentration of 5 g/ml) affected the activity of ciprofloxacin.
The combination of PAN and the iron chelators at the con-
centrations mentioned above had the same effect on the activ-
ity of ciprofloxacin as PAN alone, i.e., reducing the MIC from
0.2 g/ml to 0.05 g/ml. However, considering the synergistic
effects of PAN and iron chelators on inhibiting the growth
and biofilm formation of P. aeruginosa, it seems that combina-
FIG. 2. Growth of P. aeruginosa wild-type PAO1 and pvdA mutant in the presence of different PAN-acetohydroxamic acid combinations
(A) and PAN-EDTA combinations (B). The optical densities of the cultures were recorded after 0, 2, 4, 6, 8, 10, 12, and 24 h of incubation at
37°C. Each value represents the means and standard deviations from three wells of the microtiter dishes.
FIG. 3. Biofilm formation at the air-liquid interface of glass slides immersed in culture medium containing medium alone (A), 20 g/ml Dipy
(B), 80 g/ml acetohydroxamic acid (C), 5 g/ml EDTA (D), 50 g/ml PAN (E), 50 g/ml PAN and 20 g/ml Dipy (F), 50 g/ml PAN and
80 g/ml acetohydroxamic acid (G), and 50 g/ml PAN and 5 g/ml EDTA (H) was observed by confocal laser-scanning microscopy and analyzed
by IMARIS (Bitplane AG).
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tion treatment with PAN, iron chelators, and conventional
antibiotics reduces the risk of the development of antibiotic
resistance and tolerance.
In conclusion, we have shown here that synergistic effects
from combinations of PAN and different iron chelators could
be obtained against P. aeruginosa growth and biofilm forma-
tion. Our study suggests that combinations of EPIs and iron
chelators constitute promising therapeutic interventions
against P. aeruginosa infections. Further studies of synergies
from combining EPIs and iron chelators against P. aeruginosa
growth in vivo should be carried out.
This work was supported by a grant from the Lundbeck Foundation
and a grant from the Danish Council for Independent Research.
REFERENCES
1. Arruda, E. A., I. S. Marinho, M. Boulos, S. I. Sinto, H. H. Caiaffa, C. M.
Mendes, C. P. Oplustil, H. Sader, C. E. Levy, and A. S. Levin. 1999. Noso-
comial infections caused by multiresistant Pseudomonas aeruginosa. Infect.
Control Hosp. Epidemiol. 20:620–623.
2. Banin, E., M. L. Vasil, and E. P. Greenberg. 2005. Iron and Pseudomonas
aeruginosa biofilm formation. Proc. Natl. Acad. Sci. U. S. A. 102:11076–
11081.
3. Bernard, C. S., C. Bordi, E. Termine, A. Filloux, and S. de Bentzmann. 2009.
Organization and PprB-dependent control of the Pseudomonas aeruginosa
tad Locus, involved in Flp pilus biology. J. Bacteriol. 191:1961–1973.
4. Bodey, G. P., R. Bolivar, V. Fainstein, and L. Jadeja. 1983. Infections caused
by Pseudomonas aeruginosa. Rev. Infect. Dis. 5:279–313.
5. Clark, D. J., and O. Maaløe. 1967. DNA replication and the division cycle in
Escherichia coli. J. Mol. Biol. 23:99–112.
6. Heydorn, A., A. T. Nielsen, M. Hentzer, C. Sternberg, M. Givskov, B. K.
Ersboll, and S. Molin. 2000. Quantification of biofilm structures by the novel
computer program COMSTAT. Microbiology 146:2395–2407.
7. Holloway, B. W., and A. F. Morgan. 1986. Genome organization in Pseudo-
monas. Annu. Rev. Microbiol. 40:79–105.
8. Leive, L. 1965. Release of lipopolysaccharide by EDTA treatment of E. coli.
Biochem. Biophys. Res. Commun. 21:290–296.
9. Lomovskaya, O., M. S. Warren, A. Lee, J. Galazzo, R. Fronko, M. Lee, J.
Blais, D. Cho, S. Chamberland, T. Renau, R. Leger, S. Hecker, W. Watkins,
K. Hoshino, H. Ishida, and V. J. Lee. 2001. Identification and characteriza-
tion of inhibitors of multidrug resistance efflux pumps in Pseudomonas
aeruginosa: novel agents for combination therapy. Antimicrob. Agents Che-
mother. 45:105–116.
10. Page`s, J. M., M. Masi, and J. Barbe. 2005. Inhibitors of efflux pumps in
Gram-negative bacteria. Trends Mol. Med. 11:382–389.
11. Pamp, S. J., M. Gjermansen, H. K. Johansen, and T. Tolker-Nielsen. 2008.
Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa
biofilms is linked to metabolically active cells, and depends on the pmr and
mexAB-oprM genes. Mol. Microbiol. 68:223–240.
12. Poole, K., D. E. Heinrichs, and S. Neshat. 1993. Cloning and sequence
analysis of an EnvCD homologue in Pseudomonas aeruginosa: regulation by
iron and possible involvement in the secretion of the siderophore pyover-
dine. Mol. Microbiol. 10:529–544.
13. Poole, K., K. Krebes, C. McNally, and S. Neshat. 1993. Multiple antibiotic
resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux
operon. J. Bacteriol. 175:7363–7372.
14. Poole, K., and R. Srikumar. 2001. Multidrug efflux in Pseudomonas aerugi-
nosa: components, mechanisms and clinical significance. Curr. Top. Med.
Chem. 1:59–71.
15. Poole, K., K. Tetro, Q. Zhao, S. Neshat, D. E. Heinrichs, and N. Bianco.
1996. Expression of the multidrug resistance operon mexA-mexB-oprM in
Pseudomonas aeruginosa: mexR encodes a regulator of operon expression.
Antimicrob. Agents Chemother. 40:2021–2028.
16. Watt, S. R., and A. J. Clarke. 1994. Role of autolysins in the EDTA-induced
lysis of Pseudomonas aeruginosa. FEMS Microbiol. Lett. 124:113–119.
17. Yang, L., K. B. Barken, M. E. Skindersoe, A. B. Christensen, M. Givskov,
and T. Tolker-Nielsen. 2007. Effects of iron on DNA release and biofilm
development by Pseudomonas aeruginosa. Microbiology 153:1318–1328.
18. Yang, L., M. Nilsson, M. Gjermansen, M. Givskov, and T. Tolker-Nielsen.
2009. Pyoverdine and PQS mediated subpopulation interactions involved in
Pseudomonas aeruginosa biofilm formation. Mol. Microbiol. 74:1380–1392.
FIG. 4. Quantification of biofilms by COMSTAT. The results are means of datasets obtained from the analysis of three CLSM images acquired
at random positions in each of the biofilms. Standard deviations are shown in parentheses.
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Abstract 
We have investigated the antimicrobial effect of a set of peptidomimetics on Staphylococcus 
epidermidis  planktonic and biofilm cultures.  
An array of β-peptoid-peptide hybrid oligomers, displaying differences in amino 
acid/peptoid composition and chain length, was studied with respect to antimicrobial activity 
against S. epidermidis in both planktonic and biofilm cultures comparing the effects to those of 
the common antibiotic, vancomycin. Susceptibility and time-kill assays were performed to 
investigate the activity against planktonic cells, while confocal laser-scanning microscopy was 
used to investigate the dynamics of the activity against cells within biofilms. 
All tested peptidomimetics were bactericidal against both exponentially growing and 
stationary-phase S. epidermidis cells with similar killing kinetics. At the Minimum Inhibitory 
Concentration (MIC) all peptidomimetics inhibited biofilm formation, while peptidomimetics 
at concentrations above MIC (80-160 µg/ml) eradicated young (6-h-old) biofilms, while even 
higher concentrations were needed to eradicate mature (24-h-old) biofilms completely. Chiral 
and guanidinylated hybrids exhibited the fastest killing effects against slow-growing cells, and 
had more favorable antibiofilm properties than analogues only containing lysine or lacking 
chirality in the β-peptoid residues. However, the results of the mature biofilm killing assay 
indicated more complex structure-activity relationships. Cytotoxicity assays showed a clear 
correlation between oligomer length and cell toxicity within each subclass of peptides, but 
all possessed a high differential toxicity favoring killing of bacterial cells. 
This class of peptidomimetics may constitute promising antimicrobial alternatives for the 
prevention and treatment of multidrug-resistant (MDR) S. epidermidis infections. 
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1. Introduction 
The opportunistic human pathogen Staphylococcus epidermidis (S. epidermidis) infections 
frequently affect immunocompromised and immunosuppressed patients, especially when subjected 
to prolonged use of indwelling medical devices [1]. The prevalent antibiotic resistance and the 
capability to form biofilms have led to an increase in complications associated with the treatment of 
S. epidermidis infections [2]. Formation of S. epidermidis biofilms on the surface of indwelling 
devices such as catheters and prosthetic heart valves are difficult to treat with conventional 
antibiotics [3]. The increased antibiotic tolerance of biofilm-associated cells has been correlated to 
slow growth rate, protection mediated by extracellular polymeric substances (EPS), and the 
development of tolerant subpopulations [1, 4]. Discovery and development of novel agents for 
prevention and treatment of S. epidermidis biofilm infections are therefore urgently needed.  
Natural host-defense antimicrobial peptides (AMPs) are produced by most living organisms, and 
due to their evolved properties and alternative modes of action they are considered to be effective 
against multidrug-resistant (MDR) bacteria [5]. AMPs have also been reported to efficiently kill 
slow-growing cells from planktonic and biofilm cultures, and thus they have been proposed as 
promising alternative agents in the treatment of MDR infections [6]. Peptidomimetics are structural 
analogues of peptides containing amide bond isosteres or altered peptide backbones that result in 
higher stability as well as improved pharmacological profiles. Typically, peptidomimetics arise 
either from modification of an existing active peptide, or from the design of structurally similar 
compounds that mimic peptides e.g., β-peptides or peptoids. Appropriately designed 
peptidomimetics have been shown capable of maintaining a broad-spectrum antimicrobial activity 
while possessing advantageous properties over natural AMPs such as stability against proteolytic 
enzymes and low toxicity towards mammalian cells [7].  
Previously, we have described a synthetic approach for the design of peptidomimetics 
consisting of alternating repeats of α-amino acids and β-peptoid residues [8-10]. These studies 
suggested that one strategy to design peptidomimetics with a favorable balance between potency 
and cytotoxicity involves incorporation of chiral hydrophobic -peptoids and guanidinylated amino 
acid side chains while keeping the length relatively short. 
In the present study, we investigate the antimicrobial activity of the simple alternating β-
peptoid-peptide hybrid oligomers (i.e., 1a-3d) and the mixed amino/guanidino subtype of 
peptidomimetics (i.e., 4a-4d) against the biofilm-forming and methicillin-resistant S. epidermidis 
(MRSE) strain RP62A (ATCC 35984) in both planktonic and biofilm cultures. Their effect is 
compared with that of vancomycin, which is commonly used for the treatment of resistant or severe 
Gram-positive organisms, and thus constitutes the current antibiotic of “last resort” [11].  
 
2. Materials and Methods 
Synthesis of β-peptoid-peptide hybrid oligomers. The four mixed amino- and guanidino-
functionalized oligomers 4a-d[12] were synthesized by using our previously described solid-
 3
phase procedure [8, 10]. The -peptoid-peptide hybrid oligomers were dissolved in sterile 
deionized water (5 mg/ml) and aliquots were stored at −20 ◦C.  
     2.1. Hemolysis assay 
The hemolysis was performed as described earlier [13], detecting hemoglobin by measuring the 
OD at 405 nm; melittin (400 mg/ml) and Tris buffer (TBS; pH 7.2, 150 mM NaCl) defined 100% 
hemolysis and 0% hemolysis, respectively. 
2.2. Cytotoxicity assay 
The cytotoxicity assay was performed essentially as reported previously using HeLa cells [10]. 
Briefly, HeLa cells were incubated (37 °C, at 50 rpm) for 1 h with peptidomimetics. The tested 
concentration range was 0.1 µM to 1000 µM. The dehydrogenase activity was determined as a 
result of the amount of formazan produced as measured by absorbance at 492 nm. 
2.3. Bacterial strains and growth media 
The S. epidermidis RP62A (ATCC 35984) strain was selected as the model organism for our 
study, as it is considered a benchmark strain among the biofilm-producing S. epidermidis strains 
[14]. Tryptic soy broth (TSB; Oxoid) medium containing 0.25 % glucose was used for biofilm 
cultivation in a static chamber system. Susceptibility assays were carried out in Mueller-Hinton 
broth (MHB; Fluka). SYTO9 and propidium iodide (PI) (LIVE/DEAD reagents, Molecular Probes) 
were used at a concentration of 1 µM for staining live or dead bacteria in biofilms. 
2.4. Bacterial susceptibility assay 
Minimum inhibitory concentrations (MICs) were measured by using methods described 
previously by Wiegand et al.[15]. The MBC was determined as the lowest concentration that 
resulted in less than 0.1% survival of the subculture. All MIC and MBC determinations were made 
in triplicate. For selected compounds the MICs were also measured by using the same method in the 
biofilm media (TSB with 0.25% glucose).  
2.5. Time-kill assay in fresh MHB  
S. epidermidis cells (1×107 CFU/ml) were separately treated with β-peptoid-peptide hybrid 
oligomers at 4 µg/ml or vancomycin at 4 and 20 µg/ml in fresh MHB. Time-kill experiments were 
performed at 37 ◦C with shaking at 220 rpm under aerobic conditions. Culture aliquots (50 µl) were 
taken at different time points (0, 1, 3, 5, 8 and 24 h), serially diluted, plated onto tryptic soy agar, 
and then incubated at 37 ◦C for 24 h followed by counting of CFU. Time–kill curves were 
constructed by plotting the log10 CFU/ml versus time over a 24-h time period. Assays were 
performed in duplicate on at least two occasions, and similar results were obtained. The detection 
limit for these assays was 5×102 CFU/ml.  
2.6. Time-kill assay of stationary-phase cells in nutrient-depleted MHB  
Nutrient-depleted MHB (depMHB) was prepared by the method described previously with 
modifications [16]. Briefly, S. epidermidis was cultivated in MHB at 37 °C for 46 h. The cultures 
were centrifuged at 8000 g for 30 min at 4 °C, the supernatants were collected and adjusted to pH 
7.0, then filtered through a 0.22 µm pore size Syringe filter (TPP, Switzerland). Stationary-phase 
cells (1×107 CFU/ml) were separately incubated in depMHB in the presence of β-peptoid-peptide 
hybrid oligomers or vancomycin at 4 and 20µg/ml. Time-kill assay was performed as above. 
2.7. Biofilm susceptibility assay 
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Static chamber S. epidermidis biofilms were cultivated in a cover-glass cell culture chamber 
(Nunc, Roskilde, Denmark) as described previously [17]. Briefly, the chamber wells were 
inoculated with 1.5 ml diluted overnight cultures (5×105CFU/ml). After incubation at 37 ◦C, the 0, 6 
and 24 h preformed biofilms in the chambers were washed gently twice with sterile PBS (1 ml) to 
remove planktonic cells. Then fresh medium containing antimicrobial agents were added, and then 
the biofilm cultures were incubated at 37 ◦C for 24 h. After removal of the medium, the biofilm 
cells were stained with the LIVE/DEAD reagents, and were then observed by confocal laser-
scanning microscopy (CLSM). This assay was repeated three times, and similar results were 
obtained. 
2.8. Microscopy image acquisition and analysis 
All microscopy observations and image acquisitions were performed by using methods described 
previouslyby Qin et al. [17]. For the quantification of biofilms, at least six CLSM images from each 
sample were analysed by using the computer program COMSTAT. Error bars represent the mean + 
standard deviation. Statistical differences in comparison to control (without added antimicrobial 
agent) were determined by one-way analysis of variance (ANOVA). Differences were considered 
statistically significant with p < 0.05. 
 
3. RESULTS 
In the present study, sixteen β-peptoid-peptide hybrid oligomers (1a-4d) (Table 1, Figure 1), 
were investigated for their antimicrobial activity against both planktonic and biofilm-associated S. 
epidermidis cells as well as for their cytotoxicity towards human cells. Peptidomimetics 1a-4d are 
oligomers consisting of alternating repeats of α-amino acids and N-alkyl-β-alanine (β-peptoid) 
residues. The four examined subclasses differ in the nature of cationic side chains (amino or 
guanidino functionalized, i.e. Lys or hArg), and presence of α-chirality in the β-peptoid residues 
(βNspe or βNphe).The representative compounds of this subclass have chain lengths corresponding 
to 8-16 residues. 
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Figure 1. Chemical structures of the β-peptoid-peptide hybrids. The abbreviations used for the β-
peptoid units were adapted from those used for -peptoids [27], by adding the β-prefix: βNspe = N-
[(S)-1-phenylethyl]--alanine, βNphe = N-phenyl--alanine, hArg = homoarginine. 
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Table 1. Antimicrobial activity of peptidomimetics towards S. epidermidis and cytotoxicity against 
Hela cells.  
Subclass 
Compou
nd no. 
Mw 
(g/mol) 
MIC in MHB 
MIC in biofilm 
mediuma Hela (IC50) 
µg/ml (µM) 
MBC/
MIC µg/ml(µM) µg/ml(µM) 
1 :  
all-amino; 
-chiral 
1a 1624.81 32 (19.7) 2 >128 (>78.8)  
1b 1937.74 4 (2.06) 2 >128 (>66) >1938 (>1000) 
1c 2250.67 2 (0.89) 2 64 (28.4)  
1d 2563.60 2 (0.78) 1 16 (4.8) 
 
92 (36) 
2 :  
all-guanidino; 
-chiral 
2a 2356.38 2 (0.85) 1 ND  
2b 2815.84 1 (0.36) 1 4 (1.42) 
 
90 (32) 
2c 3275.30 2 (0.61) 1 8 (2.44)  
2d 3734.76 4 (1.07) 1 ND 
 
27 (7.2) 
3 :  
All-guanidino; 
no-chirality 
3a 2286.25 4 (1.75) 2 32 (14.0)  
3b 2732.69 1 (0.37) 1 8 (2.92) 
 
262 (96) 
3c 3179.13 2 (0.63) 1 16 (5.02)  
3d 3625.57 2 (0.55) 1 16 (4.41) 
 
40 (11) 
4 :  
amino-
guanidino 1:1; 
.chiral 
4a 935.95 >256 (>273) ND ND  
4b 1812.84 32 (17.7) 2 >128 (>70.6)  
4c 2689.72 2 (0.74) 1 16( 5.96) 
 
794 (295) 
4d 3566.61 1 (0.28) 1 4 (1.12) 
 
46 (13) 
Vancomycin  1485.71 1 (0.67) 1 2 (1.35)  
 
a biofilm media, TSB with 0.25% glucose. MIC, minimum inhibitory concentration. MBC, minimum bactericidal 
concentration. IC50, the half maximal inhibitory concentration against Hela cells. MIC, MBC and IC50 values 
represent the mean of three individual experiments. ND, not determined. The unit of µg/ml is generally used, with 
µM (micromolar) shown in parentheses. 
 
3.1. The hemolytic and cytotoxic properties of β-peptoid-peptide hybrids 
Peptidomimetics 1b, 1d, 2b, 2d, 3b, 3d had previously been found to exhibit minimal hemolysis 
(< 10%) even at a concentration of 512 μg/ml, and similarly low hemolytic activity was determined 
in the present work for compounds 4c and 4d (at 512 g/ml: <5% and 10% hemolysis, respectively) 
by using the same conditions [6]. 
From each subclass of peptidomimetics the oligomers consisting of 12 or 16 residues were 
investigated for their cytotoxicity against human HeLa cells (Table 1; IC50 is the half maximal 
inhibitory concentration), and the sequence length and content of guanidinium side chains clearly 
turned out to be the most significant structural features influencing this pharmacological property. 
Thus, potency in killing human cells increased 20-fold when extending the sequences from 12 to 
16 residues within the Lys-containing subclasses (1 and 4), whereas this effect was less pronounced 
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(3-7 fold increase) for the all-hArg analogues (i.e., 2b, 2d, 3b, and 3d). Noticeably, all 16-meric 
peptidomimetics exhibited relatively high cytotoxicity (IC50 100 M as compared to the 12-
mers containing lysine (i.e. 1b and 4c). Similarly, the lack of -chirality in the -peptoid residues in 
3b was accompanied by a 3-fold diminished cytotoxicity relative to the corresponding fully chiral 
oligomer (2b).  
3.2. Susceptibility testing in MHB and biofilm media 
The concentrations ofβ-peptoid-peptide hybrid oligomers required for inhibition or killing of 
planktonic S. epidermidis cells in MHB or biofilm media (TSB with 0.25% glucose) are 
summarized in Table 1. For subclass 1 and 4, MIC values decreased significantly with increasing 
oligomer length. Thus, chimeras 1d and 4d ranked the most potent in their subclasses, had MICs of 
2 µg/ml (0.78 µM) and 1 µg/ml (0.28 µM), respectively. In contrast, less pronounced differences in 
the MICs were found for members among subclasses2 and 3, which all were active in the range of 
1-4 µg/ml (0.36-1.75 µM). Hybrids 2b and 3b, which are dodecamers, proved most effective within 
their subclass exhibiting MICs of 1 µg/ml (0.36 µM) and 1 µg/ml (0.37 µM), respectively. The MIC 
of the reference antibiotic vancomycin was 1 µg/ml (0.67 µM). MBCs of the compounds were all 
equal to or the double of their MICs clearly indicating a bactericidal mode of action. However, it 
was found that S. epidermidis cells were less susceptible to the peptidomimetics when challenged in 
biofilm media where 2b and 4d exhibited the lowest MIC (4 µg/ml) while the MIC of vancomycin 
was 2 µg/ml. The peptidomimetics 1d, 2b, 3b, 4c and 4d all exhibited high antimicrobial activity 
and selectivity (i.e. IC50>>MIC; Table 1) in the killing of bacteria over human cells, and therefore 
these five chimeras were further investigated.  
3.3. β-peptoid-peptide hybrids efficiently kill fast-growing S. epidermidis cells 
The time-kill kinetics was investigated in fresh MHB to determine whether β-peptoid-peptide 
hybrid oligomers and vancomycin are effective against fast-growing S. epidermidis cells (Figure 2). 
Five β-peptoid-peptide hybrid oligomers (1d, 2b, 3b,4c, 4d) representing all subclasses or 
vancomycin, at a concentration of 4 µg/ml (equal to 2-4 times their MICs), were separately added to 
the cultures in order to determine their effect on cell viability as compared with untreated control 
cells. The starting inoculum was 1×107 CFU/ml. Untreated control cells grew fast (increasing 
~2log10 CFU/ml over a 24-h period). Compound 4d (4 µg/ml) exhibited the fastest bactericidal 
activity in growing cultures of S. epidermidis as it produced a 3-log reduction in CFU/ml within 1 
hour. Oligomers 1d and 2b required a longer time (3 hours) to achieve a similar bactericidal effect, 
while compounds 3b and 4c needed 5 hours to achieve a 3-log reduction in CFU/ml. Notably, 
vancomycin exhibited a more protracted bactericidal activity than the five peptidomimetics as more 
than 5 hours were required to achieve a bactericidal effect. Increasing the vancomycin concentration 
to 20 µg/ml did not improve the killing curve, which suggests that it has a concentration-
independent activity against fast-growing S. epidermidis cells. 
3.4. β-peptoid-peptide hybrids efficiently kill slow-growing stationary-phase S. epidermidis 
cells 
In order to determine whether the peptidomimetics also possessed bactericidal activity against 
stationary-phase cells time-kill kinetics was performed by using nutrient-depleted MHB (depMHB). 
Stationary-phase S. epidermidis cultures were left untreated or were treated separately with 
compounds 1d, 2b, 3b, 4c, 4d, or vancomycin at 4 g/ml (Figure 2B). It took around 3 hours for 
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compound 4d, 6 hours for compound 2b and 1d, and 24 hours for compound 4c, to produce a 
bactericidal effect (Figure 2B). Oligomer 3b caused a ~ 2-log decrease in viability after 24 hours, 
whereas vancomycin (4 g/ml) did not exhibit a killing effect under these growth conditions. 
Moreover, to determine whether the killing effects are concentration-dependent, stationary-phase 
S. epidermidis cultures were left untreated or were treated separately with the compounds at 20 
g/ml which corresponds to approximately 10 times the MIC concentration (Figure 2C). 
Compounds 2b and 4d exhibited rapid bactericidal activities with more than a 3-log reduction after 
1hour, while compounds 1d, 4c and 3b gave bactericidal effects after 3 hours, 8 hours, and 24 hours, 
respectively. Notably, vancomycin at high concentration (20 g/ml) caused a decrease of ~ 2-log 
after 24 hours. 
 
Figure 2. Time-kill curves for S. 
epidermidis RP62A upon exposure to 
β-peptoid-peptide hybrids and 
vancomycin. Cells were treated with 
compounds at low and high 
concentrations (4 and 20 µg/ml) in 
depleted MHB (B and C)as well as at 
low concentration (4 µg/ml) in fresh 
MHB (A).Viability was counted at the 
indicated time points by serial dilution 
plating. Values are the mean of 
independent tests performed in 
duplicate. CFU: colony-forming units. 
VAN: vancomycin. 
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3.5. β-peptoid-peptide hybrids inhibit S. epidermidis biofilm formation 
Next the potential of β-peptoid-peptide hybrid oligomers as prophylactic agents for preventing S. 
epidermidis biofilm formation was investigated. Thus we tested the selected hybrids at low 
concentration (≤ 1×MIC) in an assay allowing for quantification of biofilm formation by using 
fluorescence microscopy and LIVE-DEAD staining (Figure 3). At the MICs, all five 
peptidomimetics as well as vancomycin prevented formation of S. epidermidis biofilms. In 
particular, compound 2b (4 g/ml) inhibited biofilm formation corresponding to a 100% reduction 
of biomass. Furthermore, we tested whether subMICs (1-2 µg/ml) of such peptidomimetics were 
able to prevent biofilm formation. For oligomers 1d and 4c, a concentration of 2 µg/ml was used 
due to their relatively high MICs (16 µg/ml). At these subMICs, oligomers 4d (1 g/ml) and 1d (2 
g/ml) caused significant reductions of biomass (~ 65% and ~ 40%, respectively), while 
vancomycin (1 g/ml) caused 65% reduction. However, the killing effect of vancomycin appeared 
to be very heterogeneous since some parts of the biofilm were reduced, while other parts were not. 
Consequently, the remaining amount of biomass at different positions of the static chamber varied a 
lot, as reflected in a large standard deviation (Figure 3).  
 
Figure 3. Effects of antimicrobials in preventing formation of S. epidermidis (RP62A) biofilm, 
when tested at subMIC and at 1×MIC. (A): Confocal laser-scanning microscopy images. The 
biofilms were stained with SYTO9 (green fluorescent for live cells) and PI (red fluorescent for dead 
cells). The central pictures show horizontal CLSM optical sections, and the flanking pictures show 
vertical CLSM optical sections. Bars represent 20 μm. The assays were repeated three times and 
similar results were obtained. (B): COMSTAT analysis of biomass. Symbols (*, #) indicate a 
statistically significant difference (p < 0.05) with respect to the control (no antimicrobial added). 
The absence of a symbol indicates no statistically significant difference with respect to the control. 
 
3.6. Activity of β-peptoid-peptide hybrids towards young S. epidermidis biofilms 
To determine whether the selected peptidomimetics were effective also for the killing of 
bacterial cells within biofilms, CLSM in combination with SYTO9 DNA viability staining were 
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used to evaluate the produced amount of biomass as a measure of cell viability. The differences in 
bacterial survival in the biofilms were quantified by analyzing the CLSM data with the computer 
program COMSTAT [18]. For the young (6 hours) S. epidermidis biofilms, the peptidomimetics 
were added at low and high concentrations (Figure 4). At low concentrations (1-4 × MIC, 8-16 
µg/ml), peptidomimetics 1d, 2b, 4c and 4d all reduced cell viability by 80-85%, whereas oligomer 
3b had no significant effect. The reference antibiotic vancomycin (8 µg/ml) gave rise to ~50% 
reduction in live biomass, however, the killing effects of both vancomycin and oligomer 3b 
appeared to be very heterogeneously distributed within the biofilm. Nevertheless, at high 
concentrations (10-40×MIC, 80-160 µg/ml), all tested compounds almost completely disrupted 
preformed S. epidermidis biofilms (95-100% reduction of biomass) (Figure 4).  
 
 
Figure 4. Effects of antimicrobials against established S. epidermidis (RP62A) young (6-h-old) 
biofilm when tested at 8-16 and 80-160 μg/ml. (A): Confocal laser-scanning microscopy images. 
(B): COMSTAT analysis of live biomass. All symbols (* and #) indicate a statistically significant 
difference (p < 0.05) with respect to the control (no antimicrobial added). The absence of a symbol 
indicates no statistically significant difference with respect to the control. Bars represent 20 μm. 
 
3.7. Activity of β-peptoid-peptide hybrids towards mature S. epidermidis biofilms 
In the study of the killing effect towards mature (24-h-old) S. epidermidis biofilms, the selected 
peptidomimetics were tested at three different concentration levels (Figure 5). At low 
concentrations (8-16 µg/ml) only oligomer 4d (8 µg/ml) were able to cause ~43% reduction of 
viable biomass. At high concentration (160 µg/ml), oligomers 4d and 4c, as well as vancomycin 
reduced live biomass by 71%, 46%, and 50%, respectively. At 400 µg/ml, peptidomimetics 4d, 2b, 
4c and vancomycin caused significant reductions in living biomass (78%, 77%, 45% and 69%, 
respectively). Hybrid oligomers 4d and 2b were most potent in killing of mature biofilm in 
accordance with their low MICs in biofilm media and high activities against stationary-phase S. 
epidermidis cells (Table 1, Figure 3). Although, less effective than oligomer 1d in the time-kill 
study, oligomer 4c exhibited better killing effect on mature biofilm than compound 1d. Surprisingly, 
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although vancomycin was not as potent as the tested peptidomimetics in killing slow-growing 
stationary-phase cells, it exhibited a significant activity against cells in mature biofilms. The 
observed distinct heterogeneity of survival in the vancomycin-treated biofilms suggests that the 
mode of action for vancomycin is different from that of the peptidomimetics.  
 
 
Figure 5. Effects of antimicrobials against established S. epidermidis (RP62A) mature (24-h-old) 
biofilm, when tested at 8-16, 160, and 400 μg/ml. (A): Confocal laser-scanning microscopy images. 
(B): COMSTAT analysis of live biomass. Symbols (*, # and ~) indicate a statistically significant 
difference (p < 0.05) with respect to the control (no antimicrobial added). The absence of a symbol 
indicates no statistically significant difference with respect to the control. Bars represent 20 μm. 
 
4. DISCUSSION 
We set out to probe the relationship between structure (sequence composition and chain length) 
and activities (antimicrobial, antibiofilm, and cytotoxic) for a series of β-peptoid-peptide hybrid 
oligomers using the biofilm-forming and methicillin-resistant strain S. epidermidis RP62A as model 
organism. 
The susceptibility of S. epidermidis planktonic cells exhibited similar trends in structure-activity 
relationships as found in previous studies [8, 19]. Thus, a longer chain length was often correlated 
with an increased antimicrobial activity within each subclass. This tendency was more pronounced 
in lysine-containing subclasses (1 and 4) than in homoarginine-rich subclasses (2 and 3) (Table 1). 
S. epidermidis cells were found to be less susceptible to the peptidomimetics when tested in 
biofilm media (TSB+0.25% glucose) as compared to MHB (Figure 2, Table 1). This difference is 
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most likely due to the fact that S. epidermidis grow faster and reach a higher cell density in biofilm 
media than in MHB (data not shown).  
In the present study, peptidomimetics 1b and 4c were found to possess the most favorable 
cytotoxicity profiles towards HeLa cells (IC50 > 1900 g/ml and 794 g/ml, respectively), 
suggesting that a design of alternating 12-meric oligomers displaying only amino or 
guanidino/amino functional groups in a 1:1 ratio may be a promising strategy to keep the 
cytotoxicity at an acceptable level. However, the all-Lys compound 1b did not show any significant 
antimicrobial activity in biofilm medium indicating that some content of guanidino side chains is 
required for antibiofilm activity. Likewise, the hemolytic activity of 4c proved favorably low as no 
hemolysis was detected at a concentration of 256 g/ml and less than 5% at 512 g/ml. 
The finding that hArg-rich peptidomimetics belonging to subclasses 2 and 3 exhibited significant 
cytotoxicity towards human cells may be ascribed to their improved interaction with human 
membranes promoted by the ability of guanidinium groups to form bidentate hydrogen bonds with 
the phospholipids that constitute the major part of eukaryotic membranes.  
Chirality appears essential for efficient killing of both slow-growing planktonic cells and biofilm 
cultures, which corroborates preliminary studies showing that the presence of chiral β-peptoid 
residues results in higher antimicrobial potency against S. aureus, which may be due to their higher 
degree of secondary structure in compound 1d/2b vs compound 3b [8, 10]. In comparison to their 
lysine-containing counterparts (e.g., 1d, 4c), the fully guanidinylated (i.e. hArg-rich) oligomers (e.g., 
2b) exhibited faster killing of  slow-growing cells and possessed enhanced antibiofilm capacity in 
accordance with our previous studies showing that the presence of hArg residues in this type of 
peptidomimetics strongly promote activity against S. aureus. There was little correlation between 
the killing ability towards slow- growing cells compared to mature biofilms. Hybrid 4c was much 
less potent towards slow growing cells compared to compound 2b , however , 4c exhibited higher 
killing activity of mature biofilm cells than 2b. 
In particular, there is a need for studies aimed at elucidating the mode of action for these 
peptidomimetics against S. epidermidis, as well as estimating the potential resistance mechanisms 
of S. epidermidis planktonic and biofilm cells against these oligomers. The efficient killing of slow-
growing bacterial cells exerted by both AMPs and antimicrobial peptidomimetics may be due to 
their distinct killing mechanisms. Unlike conventional antibiotics that penetrate into the bacterial 
cells and interfere with intracellular targets, most AMPs and antimicrobial peptidomimetics appear 
mainly to act via pore formation or mechanisms involving transient disruption of the integrity of 
bacterial cell membranes [20]. However, there is growing evidence that several highly potent AMPs 
may in fact exert their antibacterial effect via intracellular targets [21, 22]. 
The tolerance of S. epidermidis biofilm cells towards β-peptoid-peptide hybrid oligomers may be 
due to the induction of the AMP-sensing (Aps) regulatory system [1], which is well conserved 
among staphylococci. In Staphylococcus aureus, the Aps system activates transcription of three 
genomic sequences involved in AMP resistance including mprF, dlt operon and vraFG [1]. The S. 
aureus mprF gene encodes LPG synthetase that transfers L-lysine from lysyl-tRNA to 
phosphatidylglycerol (PG) [23]. The S. aureus dlt operon is responsible for the D-alanylation of 
teichoic acid, which is a highly negatively charged component of the cell wall polymer lipoteichoic 
acid (LTA) [24]. The aminoacylation of PG and LTA results in a partial neutralization of the 
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negative charge of the S. aureus cell envelope, and thereby reduces its susceptibility towards AMPs 
[25]. The vraFG operon encodes an ABC transporter involved in resistance of S. aureus to AMPs 
and vancomycin. These resistance systems of S. aureus have homologues in S. epidermidis, 
however, further studies need to be performed in order to establish whether they are involved in 
tolerance of S. epidermidis cells towards β-peptoid-peptide hybrid oligomers [1].  
Our results obtained for the treatment of mature S. epidermidis biofilms with selected β-peptoid-
peptide hybrid oligomers and vancomycin indicate the presence of a physiological differentiation in 
mature S. epidermidis biofilms conferring overall increased antibiotic tolerance to the cell cultures 
(Figure 5). The slow-growing cells in the biofilm are not only more tolerant towards vancomycin 
but also towards the peptidomimetics. This tolerance might be due to the substantial amount of 
extracellular polymeric substances (EPS) such as poly-N-acetylglucosamine (PNAG, also known as 
PIA) and poly-γ-glutamic acid (PGA) present in surface layers of S. epidermidis biofilms [26]. Both 
PNAG and PGA protect S. epidermidis from AMPs and phagocytosis [26]. However, resistant S. 
epidermidis cells were found to be distributed randomly upon treatment with peptidomimetics 
suggesting that other mechanisms might be involved in the tolerance observed for β-peptoid-peptide 
hybrid oligomers. 
Our experiments clearly demonstrate that the present class of peptidomimetics is able to kill both 
fast-growing and slow-growing bacterial cells. Furthermore, the tested hybrid oligomers inhibited 
formation of S. epidermidis biofilm and displayed antibiofilm activity against preformed S. 
epidermidis biofilms. Also, the combined structure-activity relationships concerning their overall 
pharmacological profiles (i.e. antimicrobial activity versus cytotoxicity) indicate that these 
peptidomimetics constitute promising lead compounds towards S.epidermidis biofilm due to their 
high antibiofilm activity combined with low cytotoxicity, and negligible hemolytic activity. We 
have shown that these peptidomimetics possess bactericidal activity that is comparable, if not higher 
than the current “last resort” antibiotic vancomycin. This class of compounds should therefore be 
considered relevant alternatives in the search for novel treatment options for severe nosocomial 
Gram-positive infections.  
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Abstract 
Antimicrobial peptidomimetics are proposed as alternatives to conventional antimicrobials for 
treatment of infectious diseases caused by multiple-resistant pathogens. It is unclear how 
pathogens invoke their stress response and further develop resistance against antimicrobial 
peptidomimetics. Understanding these mechanisms is crucial for optimizing the application of 
antimicrobial peptidomimetics in the hospital. In the present study, we used Staphylococcus 
epidermidisas as a model organism to study bacterial response and resistance to a novel group of 
antimicrobial peptidomimetics which were recently developed [1]. These peptidomimetics are β-
peptoid-peptide hybrid oligomers which showed great antimicrobial and anti-biofilm activities 
compared to vancomycin against S. epidermidis.  
Transcriptomic profiles of S. epidermidis exposed to peptidomimetics and vancomycin 
suggest that peptidomimetics target the cell membrane in a similar but distinct mode as 
vancomycin. Defense against peptidomimetics involves not only general signaling pathways but 
also specific mechanisms. The VraRS regulon, ABC transporters and efflux pumps are 
differentially expressed in the response toward peptidomimetics.  
Furthermore, populations which are resistant to peptidomimetics were experimentally evolved 
by continuous passage of S. epidermidis in the presence of sub-lethal concentration of 
peptidomimetics. Comparative genomic analysis of evolved resistant populations showed 
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convergent mutations in several regulatory systems and AMP-specific targets. Among them, the 
RNAP and relA regulatory systems are thought to regulate the balance of the cells between self-
protection and nutritional capability (the SPANC balance), therefore regulating the stress 
resistance. In addition, cation transporters, efflux pumps and cell membrane modification 
enzymes were also hot spots of mutation. Transcriptomic profile of the evolved resistant 
populations reveals the importance of efflux pumps in the resistant feature. Furthermore, our 
study showed special metabolic adaptation is involved in resistance to antimicrobial 
peptidomimetics. 
To conclude, defense and resistance against peptidomimetics involves not only general stress 
system but also AMP-specific mechanisms. These results suggest that peptidomimetics may be 
alternative or additive to standard antibiotic therapy.  
Introduction 
Clinically significant antibiotic resistance has arisen against virtually every antibiotic 
developed due to the extensive usage of antibiotics[2]. Cationic antimicrobial peptides have 
gained a lot of attention as “old” but effective antimicrobial agents. Antimicrobial peptides 
(AMPs) play important roles in the innate immune system of multicellular organisms[3]. AMPs 
have a broad spectrum of antimicrobial activity against bacteria, fungi and virus[4]. In addition 
to directly killing microorganisms, AMPs can also modulate immune response such as enhancing 
antibody response, recruiting phagocytes to the site of infection[4]. 
AMPs are usually consisting of two or more positively charged amino acids (e.g. arginine, 
lysine, histidine) and a large proportion (generally >50%) of hydrophobic amino acids[3]. The 
amphipathicity of APMs allows them to easily insert into lipid bilayer of microbial membranes 
and behave as microbicide[3]. However, AMPs, as peptides, are sensitive to proteases, which are 
secreted by a wide range of microorganisms[5]. Also, many AMPs have hemolytic activity 
which further limits their application in human [6]. To overcome these drawbacks, antimicrobial 
peptidomimetics are designed based on the natural AMPs by using synthetic peptide analogues 
such asβ-peptide and peptoid as the building blocks[7]. Antimicrobial peptidomimetics have 
been shown to have great potential for treatment of infections caused by multi-resistant 
microorganisms and have already entered clinical evaluation [8]. 
Unlike many of the other conventional antibiotics which inhibit specific targets (e.g. DNA or 
proteins), most of the cationic AMPs directly interact with the negative-charged microbial cell 
membranes and disrupt cellular integrity [9]. AMPs can efficiently eradicate biofilms which 
contain persist dormant bacteria [10]. However, as AMPs belong to the ancient host defense 
effector molecules and widely exist among all high organisms, AMPs and AMP-resistance 
mechanisms are believed to be co-evolved and lead to a transient host–pathogen balance that 
further shapes the existing AMP repertoire[11].  
Bacteria have evolved specific sensing systems that activate AMP resistance mechanisms 
when exposed to AMPs[12]. The two component sensor systems PhoPQ and Aps are capable of 
sensing AMPs and regulating expression of various genes in Gram-negative and Gram-positive 
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bacteria, respectively [13-14] [15-16].  Bacteria are able to alter their cell surface charge, active 
certain efflux systems and produce proteases to become resistant towards AMPs [17]. In the 
presence of AMPs, Staphylococcus epidermidis uses its Aps AMP-sensing systems to upregulate 
AMP resistance mechanisms, including the D-alanylation of teichoic acids, addition of lysyl-
phosphati-dylglycerolto the cytoplasmic membrane, and induction of the putative VraFG AMP 
efflux pump [15]. These AMP sensing systems are usually composed by classical bacterial two-
component sensor/regulator system with structural, mechanistic, and functional differences[12]. 
How different structure groups from AMPs evoke AMP sensing systems is very complicated and 
understanding this can facilitate regional design of novel AMPs and antimicrobial 
peptidomimetics. Besides APM specific sensing systems, bacteria are also able to sense and 
respond to AMPs by general stress response systems. For example,  several sensor systems were 
activated when Bacillus subtilis was exposed to AMPs, including the SigW and SigM 
extracytoplasmic sigma factors as well as the YxdJK and LiaRS two-component systems [18].  
In the present study, we used S. epidermidis as a model organism to study stress response and 
resistance development against a novel class of antimicrobial peptidomimetics. S. epidermidisis 
is a Gram-positive and coagulase-negative staphylococci, which is part of human skin flora 
(commensal) and frequently causes infections on catheters and implants[19]. S. epidermidis cells 
were treated with sub-lethal concentrations of two of our recently developed peptidomimetics 4d, 
2b, with α-peptide/β-peptoid chimeras structures [20], and glycopeptides vancomycin (VAN). 
The stress response of S. epidermidis towards these compounds was studied by use of DNA 
microarrays.  
 Since the development of resistance to AMPs occurs slower than conventional antibiotics as 
AMPs usually attack multiple hydrophobic and/or polyanionic targets [21], it is difficult to 
obtain mutants that are resistant to AMPs. Thus experimental evolution training methods [22] by 
multiple passages with sub-lethal concentrations of 4d, 2b and VAN were  used for obtaining 
resistant populations. Whole-genome re-sequencing has been used to find the beneficial 
mutations in the resistant populations gained at the end of bacterial evolution experiments. 
Transcriptomic and phenotypic analysis was also applied to some populations or specific clones. 
Our purpose is to identify the stimulons of the peptidomimetics and to determine whether the 
differentially expressed genes play a role in the resistance. Moreover, we are interested in finding 
out whether there are strong peptide-specific responses or a more general stress response 
triggered by peptidomimetic exposure. Furthermore, through the investigations of the changes of 
the evolved resistant populations and clones on genomic, transcriptomic and phenotypic levels, 
we aim to explore the mode of action of peptidomimetics and improve our understanding of the 
microbial resistance mechanisms against the peptidomimetics. 
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Results 
Transcriptomic analysis of stress responses of S. epidermidis RP62A to antimicrobial 
peptidomimetics 
To access the response of RP62A to 4d, 2b and VAN, RP62A during log phase growth was 
exposed to the compounds at sub-lethal concentrations (see Methods) which slightly inhibited 
RP62A growth. Samples were collected after 10 min’s exposure and mRNA was isolated and 
subjected to microarray analysis. We have used the custom-made Roche-NimbleGen S. 
epidermidis GeneChip in this study, which includes probes that monitor the expression of 
virtually all ORFs from S. epidermidis RP62A genomes. 
All of the three antimicrobial compounds up-regulated a large number of genes (71, 59 or 23 
respectively). The peptides 4d and 2b induced a similar sub set of genes, and substantially 
different from induced genes induced by VAN. Table 1 shows a set of the genes induced by at 
least one of the tested compounds for at least 3-fold and represents a list of "marker" genes for 
the stress responses against these compounds. The complete list of the induced genes (higher 
than 2-fold induction) is shown in Table S1.  
4d, 2b and VAN all strongly induced the expression of the VraRS two-component system 
(SERP1422- SERP1423) and a putative cell wall-active antibiotics response protein SERP1424. 
The two-component system VraRS positively modulates the regulation of cell-wall biosynthesis 
pathway in Staphylococcus aureus [23]. The up-regulation of VraRS system suggests that the 
peptidomimetics act through targeting cell wall. 
4d and 2b treatments induced general stress response genes such as the ctsR-clpC operon, 
clpB. CtsR is the master regulator which regulates the expression of some stress response genes, 
such as Clp ATPases components (clpC, clpB). 4d treatment also induced hrcA and dnaJ [24]. 
HrcA- and CtsR-regulated genes, which encoding classical chaperones and Clp ATPases 
components, were over expressed substantially when expose S. aureus to heat shock situation 
[25].  
An obvious feature of transcriptome of peptidomimetics-treated samples was the over 
expression of efflux pumps. 4d, 2b and VAN all induced vraD (ABC transporter, ATP-binding 
protein) and SERP2131 (cation transporter E1-E2 family ATPase). In addition, 4d and 2b 
induced some other ABC transporter operons, such as oppBCDFA (oligopeptide ABC 
transporter), vraFG, SERP0097-SERP0099, sitBC, SERP0340 (ABC transporter ATP-binding 
protein), SERP0886-0889, SERP0953 (putative peptide ABC transporter, permease protein). 4d 
and 2b also induced the expression of arsenical pump (arsD, arsA), as well as some monovalent 
cation/H+ antiporters, such as SERP0281, SERP0289. The data suggests the extrusion of AMPs 
out of the cell by differential efflux pumps is a major response of S.epidermidis cells towards 
peptidomimetics.  
Furthermore, 4d and 2b largely induced the expression of several amino acid biosynthesis 
operons (dap, lys, ilv-leu, and thr operons), which are genes of intermediary metabolism. lysC 
and asd, which encode the “common-pathway” enzymes of the synthesis of all aspartate family 
amino acids, aspartokinase II and aspartate semialdehyde dehydrogenase, respectively, were 
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induced around 20 times by both 4d and 2b. The other genes encode enzymes involved in the 
biosynthesis of the aspartate family amino acids, lysine (dapA, dapB, dapD), threonine (thrC, 
thrB, hom), and isoleucine (ilvABCD,leuABCD), separately.  SERP0968 and SERP0969, 
encoding an amidohydrolase family protein and an alanine racemase family protein, separately, 
which locate next to the dap genes, were also up-regulated. Notably, lysine is a particularly 
important amino acid in Staphylococcus, being required not only as a building block for proteins 
but also as a component of the cell wall peptidoglycan. Besides, gltD, which encodes glutamate 
synthase subunit beta, was also upregulated by the two peptidomimetics. Notably, 4d caused a 
much stronger induction of amino acids production than 2b. 
Moreover, 4d and 2b and VAN treatment induced the expression of htrA (serine protease 
HtrA-like), SERP0294 (Peptidase M50B-like; pfam13398), SERP0974 (acylphosphatase), 
SERP0224 (hypothetical protein).  4d and 2b induced the expression of SERP2469 (alcohol 
dehydrogenase, zinc-containing), SERP0617 (hypothetical protein). Some genes were only 
induced by 4d, such as SERP0419 (ribosomal subunit interface protein), prsA (putative protein 
export protein), SERP0620 (hypothetical protein). There are some genes were only induced by 
VAN, such as betA and betB which are involved in osmotic balance, SERP0932 (putative 
transcriptional regulator), and SERP0551 (hypothetical protein).  
Genes down-regulated by 4d, 2b, VAN  
4d, 2b and VAN reduced the expression of 60, 42 and 20 genes, respectively. Most of the 
genes were down-regulated by more than one compound (Table S2).A striking phenomenon is 
that treatment of 4d, 2b and VAN caused down-regulation of the SaeRS operon, which is the 
regulator for several virulence factors. 
 
Experimental evolution of antimicrobial resistance in S. epidermidis RP62A 
10 independent lineages of S. epidermidis RP62A were transferred in LB media with 
increasing concentrations of 4d, 2b or VAN, respectively. As controls, 3 independent lineages of 
RP62A were transferred in LB media without addition of antimicrobial agent. In the end, after 40 
transfers (theoretically corresponds to 200 – 240 generations), 5, 4, and 3 highly resistant 
populations were evolved for 4d, 2b, or VAN, respectively (Figure S1). The experiment process 
of the development of resistance to the compounds (lineage RD14, RD22, RD33 as examples) is 
illustrated in Figure S2.  
In order to evaluate stability of the resistant phenotypes, all of the evolved resistant 
populations were cultivated in LB without antimicrobial compounds for 10 passages and their 
antimicrobial resistance were tested by micro dilution method. All the resistant populations were 
able to maintain their resistance (data not shown). The MICs of populations in LB media (MillQ) 
for 4d, 2b, and VAN were around 32-64 µg/ml, 8-16µg/ml or 8 µg/ml respectively (Table 2). 
Notably, the resistance was not detected in LB media prepared by DD H2O (Double distilled 
water), which suggests the resistance may be related to cationic concentration. In the control 
selection lineages (referred to as SET_RD0), grown in LB media without antibiotics, no 
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significant change in ABs resistance was observed compared to RP62A, indicating that antibiotic 
resistance developed due to the selection protocol (Table 2).  
There was a high degree of cross-resistance between the 4d and 2b. The populations resistant 
to one peptidomimetic are also resistant to the other at a similar degree. The peptidomimetic 
resistant populations have around 2 times higher MIC towards VAN. However, no resistance 
towards 4d or 2b was found in VAN resistant populations (Table 2).  
Comparative genomics analysis of the resistant lineages 
To investigate the genetic changes underlying adaptation, we sequenced the genomes of 12 
resistant populations belonging to 3 sets (Set RD1: RD11_P40 - RD15_P40 developed from 4d; 
Set RD2: RD21_P40 - RD24_P40 developed from 2b; Set RD3: RD31_P40 -RD33_P40 
developed from VAN), and 3 control populations belong to Set RD0 (RD01_P40-RD0_P40 
developed from non-antibiotic adding media). Notably, instead of sequence a single clone of 
each line, we sequenced the endpoint population of each line. The reference genome (RP62A, 
also named RD00 in this study) was re-sequenced to exclude polymorphisms caused by errors in 
reference assembly. 
All the 16 genomes were sequenced to an average of 114 fold coverage, generating 90 base 
paired-end reads and a total data set of 50 gigabase pairs (Gb).We identified high-quality SNPs 
in the non repetitive parts of the genomes by mapping sequence reads for each line against 
RP62A(CP000029 and CP000028). 
A total of 83 mutations were detected in the 15 populations (1-10 events per population), include 
78 SNPs, 4 microindels and 1 large deletion (~60 kb). Number of different mutations for each 
population was summarized in Table 3. 
Since we sequenced population instead of single clone, the fraction of the sequenced population 
to contain a given polymorphism was calculated (see the Table S3). This gives a very detailed 
view of the heterogeneity of the populations and showed a very high incidence of parallel 
mutations (Table 4). Specially, RD14_P40 is a pure clone which has a 100% detection of G34A 
conversion in gene relA-2 (SERP1196). 
Convergent mutations provide evidence of adaptive events. Among point mutations, 33 of the 78 
nonsynonymous (NS) mutations were shared among two or more lines, but some were shared 
extensively. Focusing on convergent mutations, we clustered them into several functional units 
(Table 5 and Table S3).  
Among these, an obvious target was the RNA polymerase complex, one of the most central 
transcriptional regulatory hubs. 2 lines in set RD2 and 2 lines in set RD3 contained a NS 
mutation in codon 508 of the RNA polymerase (RNApol) beta subunit (rpoB), and 1line in set 
RD3 contained NS mutations in codon 99 and codon 110 of the RNA polymerase (RNApol) 
beta' subunit (rpoC). 
Another key target was GTP pyrophosphokinase relA, which regulates the concentration of the 
stringent response alarmone ppGpp. 4 lines in set RD1 contained NS mutations in 6 different 
codons (12, 49, 58, 111, 534, 686) of the GTP pyrophosphokinase relA-2, RD12 in set RD1 
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contained a NS mutation in codon 179 in relA-1. GTP pyrophosphokinases are bifunctional 
enzymes which catalyze the synthesis and degradation of (p)ppGpp. The C-terminal domain is 
probably involved in the reciprocal regulation of the two catalytic activities, since truncation of 
the C-terminal domain enhances the synthesis activity of the enzyme [26]. For RD14_P40, only a 
mutation was found in relA-2.  ppGpp can interact with differential targets, decrease the 
production of ribosomes, rRNAs and tRNAs, arrest the cell cycle, but will increase the 
production of genes involved in amino acid biosynthesis and metabolisms involved in famine.  
Another target involved in stringent response is the prolyl-tRNA synthetase (proS). 2 lines in set 
RD1 and 1 line in set RD2 contained a NS mutation in codon 127 of the prolyl-tRNA synthetase 
(proS). The mutations caused decrease of prolyl-tRNA gene transcription.  
Furthermore, a striking target was the transporters and efflux pumps. 3 lines in set RD1 and 3 
lines in set RD2 contained NS mutations in 5 different codons (12, 76, 79, 82 and 102) of the 
potassium uptake protein trkA. 1 line in set RD1 and 3 lines in set RD2 contained NS mutations 
in 3 different codons (301, 298, 86) of the sodium transport family protein SERP0458. Besides, a 
NS mutation in SERP0014 (RND family efflux transporter) and a NS mutation in SERP0016 
(ABC transporter permease) were found in RD11_P40 in set RD1. 
Moreover, enzymes involve in membrane modification were also targets, such as FmtC, NagB 
and TagA. 2 lines in set RD2 contained a NS mutation in codon 176 of the 
lysylphosphatidylglycerol (LPG) synthase FmtC, which also called multiple peptide resistance 
factor (MprF). Mutation in FmtC caused decrease of negative charge of cell membrane; therefore 
weaken the ability of AMP to bind to cell memebrane. RD13_P40 and RD23_P40 contained a 
NS mutation in codon 71 of the glucosamine-6-phosphate (GlcN6P) isomerase (NagB), which 
catalyzes the reversible conversion of GlcN6P to D-fructose-6-phosphate. RD13_P40 also 
contained a NS mutation in codon 238 of UDP-N-acetyl-D-mannosamine transferase TagA. 
One nucleotide mutation was found in the intergenic area of SERP2477//SERP2478 in 
RD22_P40 (153 upstream hypothetical protein//226 downstream hypothetical protein). 
Remarkably, a large deletion (~60 kp) was found in this intergenic area in RD24_P40.  
Coexpression of the hypothetical proteins SERP2477, SERP2478 and sdrH were found in 
S.epidermidis (http://string-db.org/). sdrH is a cell-surface-associated protein, a member of  
serine-aspartate repeat (Sdr) protein family in S.epidermidis [27]. Conserved domains blast 
shows that SERP2477 belongs to the TIR_2 super family. This is a family of bacterial Toll-like 
receptors. Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate 
immune system. They are single, membrane-spanning, non-catalytic receptors that recognize 
structurally conserved molecules derived from microbes.  
NS mutations were found in translation initiation factor IF-2 (InfB) in populations RD02_P40, 
RD11_P40, RD22_P40, and RD32_P40, in 4 different codons (230, 264, 309, 646) respectively. 
Previous studies proved that mutations in the metY-nusA-infB operon suppress the slow growth 
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of a ΔrimM mutant in E.coli, by increasing the synthesis of the ribosome binding factor RbfA 
[28]. Mutations in infB may suppress the slow growth rate caused by other mutations. 
One nucleotide mutation in the intergenic region of SERP2096//SERP2097 were found in 3 lines 
in set RD0, 1 line in set RD1 (RD13_P40), and 1 line in set RD2 (RD23_P40). The intergenic 
region is the upstream of both genes. SERP2096 is a putative perfringolysin O regulator protein, 
a phosphotransferase system IIC component, glucose/maltose/N-acetylglucosamine-specific 
which involved in carbohydrate transport and metabolism. No conserved domain was found in 
SERP2097. 
One indel in RD01_P40, one NS mutation in RD03_P40, and one nonsense mutation in 
RD33_P40 were found in gene encode SERP0927. A mutation of C->T was found at the 
intergenic region of parC//SERP0927 (10 downstream DNA topoisomerase IV, A subunit//202 
upstream amino acid carrier protein) for RD32_P40 and RD33_P40.  SERP0927 is an amino 
acid carrier protein, Na+/alanine symporter, which involved in amino acid transport and 
metabolism. 
A NS mutation of either G666T or G666A was found in all the 3 populations of set RD3, which 
caused M222I change (Met changed to Ile) in the sensory box histidine kinase YycG.  The 
YycF/YycG two-component regulatory system (TCS) of Staphylococcus aureus represents the 
only essential TCS that is almost ubiquitously distributed in low G+C Gram-positive bacteria. 
YycG (WalK/VicK) is a sensor histidine-kinase and YycF (WalR/VicR) is the cognate response 
regulator. Both proteins play an important role in the biosynthesis of the cell envelope. Mutations 
in YycG have been involved in development of resistance against vancomycin [29] and 
daptomycin [30]. Notably, a mutation prevalence study showed that the mutation of YycGF was 
most frequently carried by Vancomycin-intermediate Staphylococcus aureus (VISA) strains [29]. 
Gene expression changes of the evolved populations  
 
To study the mechanisms involved in adaptive evolution, mRNA transcriptional profiling was 
performed at the endpoint of evolution for evolution populations RD11, RD14, RD21 and RD31. 
Gene expression changes of RD14 and RD11 
The genes induced both in RD14 and RD11 were SERP0014- SERP0016 (encode RND and 
ABC transporters), SERP0915 (encodes an IS256-like transposase), SERP0061 (encodes a 
putative 2-keto-4-pentenoate hydratase) and SERP0224 (encodes a hypothetical protein). 
Notably, SERP0014, SERP0015 and SERP0016 were up regulated for around 10 times in both 
populations. 
The most strongly induced genes in RD14 were the virulence genes ica operon (icaBCD which 
encode intercellular adhesion proteins) which have been induced for around 15 times. Other 
genes induced in RD14 were the SERP0311-0313 (which encode the Aps (antimicrobial peptide 
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sensing) system), vraFG (encode an ABC transporter), genes encode various dehydrogenases 
(asd, ald, serA, SERP2469), sdhA and adhB (L-serine dehydratase), and so on. 
betA and betB, which involved in osmotic balance, were induced in RD11. SERP2279, a gene 
locates next to secY (encodes preprotein translocase subunit SecY), was also up regulated in 
RD11. 
Genes down regulated in both RD14 and RD11 were the ure operon (encode urease), SERP1972 
(encodes an AraC family transcriptional regulator), geh-2 (encodes a lipase).  
Besides, some other genes were down regulated in RD14, such as SERP0736-0739 (phenol 
soluble modulin beta 1); glpFK (glycerol uptake facilitator protein and glycerol kinase); hld 
(delta-hemolysin); sarV (accessory regulator V); SERP2161 (putative lipoprotein); SERP1968 
(PTS system, sucrose-specific IIBC components) and geh-1(encodes a lipase). 
SERP2417 and SERP1627, which encode a putative lipoprotein and a hypothetical protein 
respectively, were down regulated in RD11. Notably, SERP1972 and SERP2161 were also down 
regulated when S. epiderdimis cells exposed to sub-lethal concentration of 4d (Table S4). 
 
Gene expression changes of RD21 and RD31 
Remarkably, for RD21 and RD31, the expression pattern of a large fraction of genes (21% and 
15% respectively) was changed (Table S5). A single mutation to a regulatory hub can result in 
large-scale changes to the expression state of cells in the mutated population [31]. Studies 
showed that a single mutation in rpoC changed the expression pattern of 20–27% of genes in the 
genome of the mutated population [32]. Therefore the mutation of RNA polymerase beta subunit 
(rpoB) may result in the broad-scale changes to the expression in RD31. It’s surprising that even 
only one point mutation in a sodium transport family protein (SERP0458) was found in 95% of 
the RD21 population, the expression pattern has been change strongly.  
 
RD14, relA-2 and ppGpp 
 
According to the genome sequence data, there is only one point mutation in relA-2 in 100% of 
the RD14 population, which means RD14 it’s a pure clone. We streaked out RD14 population on 
LB plate and the colonies were obvious smaller than RP62A wide type colonies. Some colonies 
were picked out and tested for MIC values. All of them have the same MICs towards 4d as the 
RD14 population. A colony was picked randomly and named RD14-1. 
The mutation (V12M) in the RD14 chromosome relative to that of RP62A locates to the N-
terminal ppGpp regulatory domain of RelA, replacing a valine that is conserved in Gram-positive 
species (not shown). 
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In order to examine whether the relA mutation caused any perturbation of the ppGpp pool, the 
RD14-1 and its ancestor RP62A were grown in chemically defined media with amino acid and 
radioactive phosphate, labelling its nucleotides. The generation times of RP62A and RD14-1 
were 48 minutes and 83 minutes respectively. The ppGpp pool was 24.5 pmol/OD600 in RD14, 
while the compound was virtually undetectable in the ancestral strain (Figure S3). 
In Gram-positive bacteria, the transcriptional basis of the stringent response is largely mediated 
through altered balance between the adenine and guanine branches of the purine interconversion 
pathways as IMP dehydrogenase is inhibited by ppGpp, thus giving lower flux towards GTP. 
Therefore, we determined the pool sizes of the remaining nucleotides. The ATP pool sizes were 
of equal size in the two strains (1.41±0.36 nmol/OD600 in RP62A and 1.31±0.17 nmol/OD600 in 
RD14-1), while the other nucleoside triphosphate pools were lower in RD14-1. Especially the 
GTP pool was less than half the size: 0.41±0.12 nmol/OD600 in RP62A and 0.17±0.01 
nmol/OD600 in RD14-1. The ATP/GTP ratios were thus 3.4 and 7.7. The difference was also seen 
on the nucleoside monophosphate level as there were 9.7±0.4 pmol/OD600 and 8.9±0.1 
pmol/OD600 AMP and 2.3±0.8 and 1.4±0.4 pmol/OD600 GMP in RP62A and RD14-1, 
respectively (Figure S4). 
According to the array data of RD14 (Table7, Table S4), the transcriptomic response to the relA 
mutation: Many genes of diverse function had altered expression in RD14 relative to RP62A, 
suggesting that the effects of the mutation are driven by changes relating to altered growth rate or 
pleiotropic small molecule-mediated regulation. 
Discussion 
Stress response against peptidomimetics 
The strongly induction of the VraRS regulon suggests that the peptidomimetics 4d and 2b work 
through the interaction with cell wall. Besides targeting membranes, several AMPs such as 
bacitracin and nisin inhibit cell wall biosynthesis [33-34]. A transcriptomic profiling study with 
daptomycin, a lipopeptide antibiotic,  also showed induction of the VraRS regulon, which is 
probably caused by the effects on the cell wall biosynthesis inhibition as well as membrane 
depolarization [35-36]. The humanβ-defensin 3 has also shown a similar dual effect [37]. Our 
previous killing kinetic studies have shown that our peptidomimetics kill bacterial cells much 
faster than Vancomycin (data not shown). Therefore, these peptidomimetics may also have both 
cell wall biosynthesis inhibition and membrane depolarization effects.  
Over expression of a lot of ABC transporters and putive efflux pumps suggests extrusion of 
peptidomimetics out from cell cytoplasm is a prominent mechanism. The expression of vraFG 
ABC transporter is under the control of the Aps (GraRS) sensor system, which also controls the 
expression of dlt system, encoding components which catalyze the D-alanylation of teichoic 
acids, and mprF, encoding the MprF enzyme responsible for the lysinylation of phospholipids of 
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the membrane [15]. However, the dlt system and mprF genes were not induced upon exposure to 
peptidodomimetics.  
Furthermore, S. epidermidis cells try to adapt to the stress and harmful effects of 
peptidomimetics by inducing some general stress response genes. The highly increased 
production of several amino acids in the peptidomimetics treated cells is probably a consequence 
of stringent response cause by amino acid starvation.  
Experimental resistant development against peptidomimetics 
Adaptive laboratory evolution (ALE) can be used to address fundamental questions about 
adaptation to selection pressures, and ultimately, the process of evolution. High-throughput 
technologies, systems biology and microbial genetics have provided insights into bacterial 
adaptation on phenotypic and genotypic levels [38]. ALE studies have been performed under 
various selection pressures, such as nutrition-limited medium, high temperature and antibiotic 
treatment. What we have learnt from the previous ALE studies were: First, the complete set of 
mutations in either clonal or population samples can be determined by next-generation 
sequencing technologies. Second, adaptive mutations frequently target regulatory mechanisms, 
such as RNA polymerase. Third, systems-level optimization principles underlie the genetic 
changes seen in adaptive evolution. Fourth, diversity in evolving populations is related to the 
mutation rate, the fitness effects of beneficial mutations, and the size of bottleneck involved [38-
39].  
In our study, a very high incidence of parallel mutations was found in the experimental 
developed resistant populations. The convergent mutations can be clustered into several 
functional units, i.e., RNA polymerase (RNAP) complex, GTP pyrophosphokinase RelA, 
transporters and efflux pumps and enzymes responsible for membrane modification. Mutations 
in the RNAP and RelA regulatory systems have been frequently detected in experimental 
evolution studies. RelA regulates the concentration of stringent response alarmone ppGpp. 
ppGpp affects the replication, transcription, and translation of the resource-consuming cell 
processes, through the interaction with various targets, such as RNA Polymerase, translational 
GTPases, DnaG primase and IMP dehydrogenase [40-42]. Differently, mutations in transporters, 
efflux pumps and cell membrane modification enzymes are responsible to more specific AMP 
resistant mechanisms. Notably, the membrane modification mechanism was not detected in the 
transcriptional profiling of the stress response assay.   
Regarding to the transcriptomic profiling of the RD14 and RD11 population, the most prominent 
feature is the strong induction of SERP0014- SERP0016 (RND and ABC transporters) and an 
IS256-like transposase. The mutation of relA-2 in RD14 even caused induction of Aps system 
and induced the expression of VraFG ABC transporter. The Aps system may play an important 
role in sensing and respond to the presence of peptidomimetics. The S. epidermidis 1457 apsS 
and apsX mutants become much susceptible toward 4d and 2b compared to wild-type strain (data 
not shown). Moreover, the pleiotropic effects of relA-2 mutation have changed the expression of 
various genes. 
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relA-2 and ppGpp 
 
Since the RD14 is a pure clone containing a 100% point mutation in relA-2. It becomes a good 
sample for studying the regulation of relA and stringent response in S. epiderimidis. 
The nucleotide pool determinations clearly demonstrate that the mutation in RD14 causes an 
increased level of ppGpp. The regulatory responses of ppGpp are highly diverse among bacteria 
and are linked to many traits [43]. The ppGpp pool might determine for the balance between 
adenine and guanine nucleotide pools, which influences the rate of transcription initiation of 
some promoters, especially those of ribosomal RNA. In E. coli, ppGpp is essential for regulation 
of the rRNA content [44]. Gram-positive bacteria do not rely on stringent sequences in the 
promoter, nor ppGpp and DksA in the stringent response [45]. Rather the ppGpp inhibits IMP 
dehydrogenase, which in turn changes the balance between the ATP and GTP nucleotide pools 
and subsequently influences transcription initiation. The size of the GTP pool also influences 
transcription as a co-repressor of the CodY repressor in some firmicutes – in addition to the 
regulation by branched chain amino acids. A lower GTP pool will release repression of the CodY 
targeting genes. The transcriptomic analysis we have conducted here reveals that there is some 
overlap between genes induced in RD14 and those most up-regulated in a S. aureus codY null 
mutant such as the ica operon and binds to CodY [46-47]. 
A ppGpp-up mutation causing a growth inhibition as accompanied by a high counter-selective 
pressure, but nevertheless this experiment has shown that it can even be selected for under 
treatment with a sub-lethal concentration of an antibiotic. 
Recently, small single-domain (p)ppGpp synthetases have been identified in firmicutes by 
homology to the C-terminal domain of Rsh (RelA-SpotT Homologs) proteins. The genes are 
present in S. aureus, named relP and relQ (4), and by homology search we find homologs in the 
RP62A genome as well: SERP2065 (relP, 79% identical on amino acid level) and 
SERP0586/relA-1 (relQ, 92% identical). These enzymes carry only the synthesis function and 
are thus not capable of hydrolysis, suggesting the hydrolysis function relies on functional Rsh 
protein, and in line with this a we note that a full deletion of rsh has not been possible to obtain 
in S. aureus [48]. 
The mutation isolated here can be explained by a partial loss of ppGpp hydrolysis caused by 
either an enzyme with less hydrolytic activity or by altered expression of the gene. The V12M 
mutation is due to a GTG to ATG codon substitution. An analysis with the RBS calculator 
software (https://salis.psu.edu/software/reverse) [49] reveals that the nucleotide substitution at 
the twelfth codon rises the probability of a higher translation start rate here, but not matching that 
of the annotated start codon, which is a GTG. 
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Conclusion 
 
S. epidermidis cells respond to the stress caused by peptidomimetics through either general stress 
response systems or specific mechanisms. The VraRS regulon and Aps (GraRS) system are 
responsible for sensing and reacting to the peptidomimetics. Differential ABC transporters and 
efflux pumps are involved in the repulse of harmful peptides from cells.  
Adaptive evolution of the S. epidermidis cells toward the peptidomimetics caused mutations in 
regulatory systems and genes of simple specific roles. RNAP and relA are the most frequently 
mutated regulatory targets. To some extent, both of them regulate the balance of the cells 
between self-protection and nutritional capability (the SPANC balance), therefore regulating the 
stress resistance. Cation transporters, efflux pumps and cell membrane modification enzymes 
were also hot spots of mutation. Notably, the membrane modification mechanism seems only 
detected in the adaptive resistant but not in the stress response studies. 
Furthermore, the phenotypic and transcriptomic studies of the relA-2 mutant RD14 has provided 
detailed information about the relA regulated stringent response in S. epiderimids. Briefly, the 
V12M mutation of relA-2 causes an increased pool of ppGpp. The accumulated ppGpp inhibites 
IMP dehydrogenase, which in turn lowers the GTP/ATP ratios and subsequently influence 
transcription initiation of various genes, including stress response genes and importantly, the 
genes encoding the Aps system and VraFG transporter.  
To summary, general stress response especially the stringent response is an important 
mechanism for S. epidermidis to respond to peptidomimetic 4d and 2b. In addition, some 
specific mechanisms are involved to the defense of peptidomiemtics, such as the VraRS and Aps 
sensor systems, various efflux pumps and membrane modification enzymes. These results 
suggest that peptidomimetics could constitute a potential additive to conventional antibiotic 
treatment.  
Material and methods 
Bacterial strains, chemicals, and growth conditions. Staphylococcusepidermidis RP62A was 
used as a reference strain. Peptidomimetics were synthesized as previously described [50-
52] .Vancomycin was purchased from Sigma. LB broth (prepared in MillQ water) was used for 
the resistance develop assay and the MIC testing.TSB media with 0.25% glucose was used as 
growth medium for all the microarray study. 
Determination of minimum inhibitory concentration. The minimum inhibitory concentration 
(MIC) was determined using a standard broth microdilution technique as previously described 
[53]. The MIC was determined as the lowest concentration where no visible growth occurred.  
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Resistant bacteria were taken directly from the frozen culture to minimise a possible loss of 
induced resistance by incubation without the presence of ABs. To exclude differences in the 
MIC due to testing directly from frozen culture the wild-type RP62A strain was tested directly 
from frozen culture and from overnight culture. No difference in MIC was observed between the 
two testing methods. All assays were performed in duplicate and on at least two separate 
occasions.  
Develop of resistant mutants/populations. Serial passage was initiated from overnight cultures 
and added to LB medium containing antibiotics (1:100 dilutions; Final bacterial concentration of 
approximately 1.0×107 CFU/ml). The bacteria were incubated overnight at 37℃ and an aliquot 
was transferred to a new tube with a higher concentration of relative antibiotic. No antibiotic was 
added to the LB media for the first transfer. From passage no. 2, a non-inhibitory concentration 
of antibiotic of 0.5 μg/ml was used (The RP62A strain has MICs of around 2 µg/ml for all the 
three tested antimicrobial agents before the passages). The primary passages in the presence of 
sublethal MICs resulted in induced resistance at various levels at all tested conditions. Several 
resistant strains were further passed in medium with increasing concentrations of different 
compounds. At some transfers such as transfer no. 9 for lineage RD14, the experiment was 
started from frozen culture sample (Figure S2). Concentration was doubled after every 3 stable 
passages under a concentration. Each mixed-population sample was periodically frozen in 25% 
(w/v) glycerol at -80℃.  The stability of the induced resistance was determined by serial 
passages in medium without antibiotics. 
Sample preparation for genome sequencing. We revived mixed populations from frozen 
cultures of the end of the evolution experiments, by growing them overnight at 37℃ with 
shaking at 200 rpm in LB media. Overnight culture was centrifuged. Bacteria pellet was 
resuspended in 100 µl lysis buffer (500 µg/ml lysostaphin in 50 mM EDTA (pH 7.5)) for 30 min 
at 37°C. Whole genome DNA was purified using Wizard genomic DNA purification kit 
(Promega).Whole genome DNA of 12 resistant populations(5 lines developed from 4d, 4 lines 
developed from 2b, 3 lines developed from VAN), 3 control populations together with the 
reference RP62A, in total 16 genomes, were prepared for sequencing. 
Genome sequence and mutation analysis. Samples were sequenced on an Illumina Hiseq2000 
platform generating 90 base paired-end reads.Reads were mapped against the genome of RP62A 
(Genbank accession numbers CP000029 and CP000028) using Novoalign (Novocraft 
Technologies) [54]. Average insert sizes were 468 nucleotides, and the average genomic 
coverage depths were 112-116 fold. Pileups of the read alignments were produced by SAMtools 
release 0.1.7 [55]. Single nucleotide polymorphisms were called by the varFilter algorithm in 
SAMtools in which minimum SNP coverage was set to 3 (samtools.pl varFilter‐d 3 ‐D 10000). 
Only SNP calls with quality scores (Phred‐scaled probability of sample reads being homozygous 
reference) at least 20 (i.e.P≤0.01) were retained. Microindels were extracted from the read pileup 
by the following criteria; (1) quality scores of at least 500, (2) root-mean-square (RMS) mapping 
qualities of at least 25, and (3) support from at least one fifth of the covering reads. To avoid 
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false-positives, the reference genome was re-sequenced to exclude polymorphisms caused by 
errors in reference assembly. The fraction of the sequenced population to contain a given 
polymorphism was calculated as the number of reads supporting the polymorphism divided by 
the total number of reads.  
Determine the sub-lethal concentrations. To determine the sub-lethal concentrations of  4d, 2b 
and VAN, 50 ml of TSB+0.25%glc medium was inoculated with approximately 5x106 
S.epidermidis RP62A cells (OD600 = 0.01) in 250ml flasks, the cultures were incubated with 
shaking at 250rpm at 37°C. Antibiotics were added in the early exponential phase (OD600 = 0.3) 
in several concentration levels. OD600 value was measured every 30min and the growth kinetics 
were drawn. The addition of the ABs at these sub-lethal concentrations (2 μg/ml of 4d, 2 μg/ml 
of 2b, and 5 μg/ml of VAN) slowed down the growth slightly.  
Sample preparation for microarray  
For testing the stress response of wide type RP62A towards antibiotics, bacteria were grown in 
TSB medium with 0.25% glucose to the early exponential phase (OD600 = 0.3) and antibiotics 
were added at the sub-lethal concentrations described above. Samples were taken for RNA 
isolations after treating the cultures with the compounds for 10 minutes. Control cultures without 
antibiotic additions were treated similarly and in parallel. While for the resistant populations, 
samples were harvested at early exponential (OD600 = 0.3) without being exposed to any 
antibiotics. 
The cells from 4 ml of the cultures were immediately mixed with RNAprotect Bacteria Reagent 
(Qiagen) and stored at -80°C. RNA isolation was performed by use of a FastPrep BLUE (Q-
BioGene) kit and following the protocol described before [56]. Purified RNA samples were 
analyzed using the RNA NanoLab chip on the 2100 Bioanalyser (Agilent, Palo Alto, CA). 
Triplicate experiments were performed for each treatment. For all experiments, the same 
amounts of RNA were used. 
Microarray experiments and data analysis. DNA microarrays with probes for RP62A strain 
and plasmid pSERP were designed and manufactured on 12x135K slides by Roche-NimbleGen 
(http://www.nimblegen.com) from the GENBANK entries. cRNA synthesis and labelling was 
performed with a modification of the low-Input Quick Amp labelling kit from Agilent (Gautier et 
al., unpublished protocol), using only Cy3 as the only dye. After washing according to the 
NimbleGen protocol for expression arrays, the slides were scanned with a Roche 2-micron 
scanner and the images processed with Nimble Scan v.2.5.The data obtained in the XYS format 
were pre-processed with the help of the bioconductor suite of tools [57] and differential 
expression patterns identified with the LIMMA package and the method TREAT [58], using a 
log2 fold change of 1 as a prior. Genes showing significant changes (P < 0.05) and at least a 2-
fold induction/reduction of expression, in the antibiotic-treated cells as compared to the control 
cells (non-treated) were accepted as differentially expressed. 
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Nucleotide pools assay. RP62A and the single-colony isolate RD14-1 were grown in the 
chemically defined SA-media [59] supplemented with glucose to 1% at 30°C. Cultures growing 
exponentially were diluted in preheated media to an optical density at 600 nm (OD600) of less 
than 0.05. At OD600 = 0.2, 150 µL was transferred to 1 µL of [33P]-labelled orthophosphate 
treated with inorganic pyrophosphates as previously described [60]. At OD600 around 0.8 to 0.9, 
100 µL of the radioactively labelled culture was transferred to 20 µL of 10 M HCOOH stored in 
an Eppendorf tube at -20°C, vigorously mixed and transferred to dry ice. Nucleotides were 
extracted [60], separated and quantified as described [61-62], except for ppGpp which was 
quantified by one-dimensional TLC of the raw nucleotide [63]. The compounds contributing to 
the intensity of the ppGpp spot was found to bind charcoal. The experiments were done in 
duplicate, and each pool size is reported as average ± standard deviation. 
 
Tables 
Table 1. Genes induced by 4d, 2b, VAN 
 
Gene ID Gene 
Name* 
Down regulated with** Known 
Regulation in 
SA*** 
Protein/Similarity 
4d 2b VAN 
SERP0019       7.9   hypothetical protein 
SERP0021       vraD 2.9 4.4 19.8  AMP, VCM ABC transporter, ATP-binding protein 
SERP0099   4.7 3.5     ABC transporter, substrate-binding protein 
SERP0109 gltD 5.5 2.9    AMP, VCM glutamate synthase subunit beta 
SERP0162 ctsR# 7.8 4.4    AMP transcriptional regulator CtsR 
SERP0224   5.3 3.4 3.5  AMP, VCM hypothetical protein 
SERP0294   3.9 3.2 5.9  AMP, VCM hypothetical protein 
SERP0314 vraF 2.7 3     ABC transporter, ATP-binding protein 
SERP0419   7.2 2.9     ribosomal subunit interface protein 
SERP0564 clpB 10.4 9    AMP, VCM ATP-dependent Clp protease, ATP-binding subunit ClpB
SERP0570 oppB# 5.8 2.8    AMP, VCM oligopeptide ABC transporter, permease protein
SERP0617   6.9 4     hypothetical protein 
SERP0620   4.7       hypothetical protein 
SERP0887   4.7 7.7     ABC transporter, permease protein 
SERP0896   3.7       aspartate kinase 
SERP0897 hom 9.7 4.6    AMP, VCM homoserine dehydrogenase 
SERP0898 thrC# 9.5 4.7    AMP, VCM threonine synthase 
SERP0963 lysC 25.1 21.5    AMP aspartate kinase 
SERP0964 asd 22.6 17.6    AMP, VCM aspartate-semialdehyde dehydrogenase 
SERP0965 dapA# 12.8 7.4    AMP, VCM dihydrodipicolinate synthase 
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SERP0968   12 7.1    AMP, VCM amidohydrolase family protein 
SERP0969   7.5 6.8    AMP alanine racemase family protein 
SERP1292 htrA 9.7 4.6 3.4  AMP, VCM serine protease HtrA, putative 
SERP1422 vraR# 9.7 6.4 6.1  AMP, VCM DNA-binding response regulator VraR 
SERP1424   10.1 6.8 6.7  AMP, VCM hypothetical protein 
SERP1425   5.5   2.9  AMP, VCM hypothetical protein 
SERP1667 ilvI 8.4 3.7    AMP acetolactate synthase 1 regulatory subunit 
SERP1668 ilvC# 30.9 6    AMP ketol-acid reductoisomerase 
SERP1669 leuA# 23.2 4.2    AMP 2-isopropylmalate synthase 
SERP2017     3.2     amino acid permease family protein 
SERP2131   8.5 6.1 7.7  AMP, VCM cation transporter E1-E2 family ATPase 
SERP2159   4 3.7    AMP, VCM 4-aminobutyrate aminotransferase 
SERP2428 arsA# 4.1 3.3     arsenical pump-driving ATPase 
SERP2469   8.9 6.6     alcohol dehydrogenase, zinc-containing 
SERP2541   4.2 5.1    AMP homoserine O-acetyltransferase, putative 
*: Only the most strongly induced genes, the marker genes, are shown in this table. The complete list of genes 
induced at least 2-fold by several ABs is shown in Table S1.  
#: In the case of operons, only the first gene or the most strongly induced gene is shown. 
**: 4d, 2b, VAN: RP62A exposed to sub-lethal concentration of 4d, 2b or VAN respectively.   
***: VCM, vancomycin inducible; AMP, AMP inducible. Data are from a microarray study on S. aureus against 
linear CAMPs [64] 
Table 2. MICs (μg/ml) of the resistant populations in LB (MillQ) * 
 
 
  4d  2b  VAN 
original strain  RP62A 2 2 2 
populations  
developed from 4d  
RD11_P40** 64 32 2 
RD12_P40 32 16 2 
RD13_P40 64 64 4 
RD14_P40 64 32 4 
RD15_P40 64 16 2 
populations  
developed from 2b  
RD21_P40 8 16 2-4 
RD22_P40 8 16 2 
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RD23_P40 16 8 2-4 
RD24_P40 8 16 4 
populations  
developed from VAN 
RD31_P40 2 2 8 
RD32_P40 2 2 8 
RD33_P40 2 2 8 
controls  
RD01_P40 2 2 2 
RD02_P40 2 2 2 
RD03_P40 2 2 2 
* Populations were cultivated in LB without antibiotics for 10 passages and they were still resistant  
** RD11_P40 stands for the population after passage no. 40 in lineage RD11. 
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Table 3. List of mutations during adaptive evolution (parallel evolution) 
 
      
Set RD0 
(CK) Set RD1 (4d) Set RD2 (2b) Set RD3 (VAN) 
Locus tag 
Gene 
name 
R
D 
0
0 
R
D 
0
1 
R
D 
0
2 
R
D 
0
3 
R
D 
1
1 
R
D 
1
2 
R
D 
1
3 
R
D 
1
4 
RD
15 
RD
21 
RD
22 
RD
23 
RD
24 
RD
31 
RD
32 
RD
33 
SERP2096//SE
RP2097 //   2 2 2     2         2         
SERP0927     2   2                   2 1 2 
SERP0836 infB     2   2           2       2   
SERP1272//SE
RP1273 ald//   2 2 2                         
SERP1126//SE
RP1127 // rpoD   2                             
SERP1312     2                             
SERP1680 rsbU   2                             
SERP1849//SE
RP1850 
sarV// 
moaA     2                           
SERP1159       2                           
SERP1820 rplX     2                           
SERP1955  mqo-1       2                         
SERP1382         2                         
SERP2163//SE
RP2164 //       2                         
SERP0674           2 2     2   2 2 2       
SERP0014           2             1         
SERP0016           2                       
SERP1196  relA-2           2 2 2 2               
SERP0830 proS           2 2         2         
SERP0586  relA-1           2                     
SERP0588             2                     
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SERP0458               2     2 2 2         
SERP0215 nagB             2         2         
SERP1584//SE
RP1585 // aacA             2         2         
SERP0295 tagA             2                   
SERP1055 srrA             2                   
SERP0930 fmtC                   1   2 2       
SERP1465                       2           
SERP2547                       2           
SERP2477//SE
RP2478 //                     2   2       
SERP0183 rpoB                       2 2 2 2 1 
SERP2533 yycG                           2 2 2 
SERP1916//SE
RP1917 //                           2     
SERP0184 rpoC                             1 2 
SERP0581                               2 2 
SERP0926//SE
RP0927 parC//                             2 2 
SERP1330                               2 2 
SERP1731//SE
RP1732 
murAB// 
fbaA                             2 2 
SERP1688                                 2 
SERP0343                                 2 
:SNP called by SAMtools;        :SNP may be present but not called by SAMtools. // : the mutation locates 
between the two genes. 
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Table 4. Number of different mutation events for each population 
 
Number 
of events 
RD 
01 
RD
02 
RD 
03 
RD 
11 
RD 
12 
RD 
13 
RD 
14 
RD 
15 
RD 
21 
RD 
22 
RD 
23 
RD 
24 
RD 
31 
RD 
32 
RD 
33 
In 
total 
SNPs 4 7 6 4 5 10 1 2 1 7 9 3 3 7 9 78 
short 
indels 2                       1   1 4 
large 
deletion*                       1       1 
In total: 6 7 6 4 5 10 1 2 1 7 9 4 4 7 10 83 
*, large deletion (>30bp) 
 
Table 5. Convergent mutational events in functional unit level 
 
Function unit Fraction of mutated lineages (No. of mutation events)* 
Mutational 
type# 
NOTE 
  Gene name 
Set 
RD0 
Set RD1 
Set 
RD2 
Set 
RD3 
    
Extended 
RNApol 
complex 
 rpoB     
2/4 
(1)** 
2/3(1) a 
DNA-directed RNA polymerase 
subunit beta 
rpoC       1/3(2) a 
DNA-directed RNA polymerase 
subunit beta' 
//rpoD 1/3 (1)       e 
conserved HP***//RNA polymerase 
sigma factor RpoD 
General stress 
response 
regulation 
 relA-1   1/5 (1)     a GTP pyrophosphokinase 
 relA-2   4/5 (6)     a,b GTP pyrophosphokinase 
 
ald//SERP127
3 
3/3 (1)       e 
alanine dehydrogenase//universal 
stress protein 
 proS   2/5 (1) 1/4 (1)   a  prolyl-tRNA synthetase 
Transpoter,eff
lux pump 
trkA   3/5 (2) 3/4 (3)   a  potassium uptake protein 
SERP0458   1/5 (1) 3/4 (3)   a sodium transport family protein 
SERP0014   1/5 (1)     a 
RND family efflux transporter, MFP 
component  
SERP0016   1/5 (1)     a ABC transporter permease 
 Membrane 
modification 
 fmtC(mprF)     2/4 (1)   a 
 LPG synthase. lysylation of 
phospholipids 
tagA(SERP02
95) 
  1/5 (1)     a 
UDP-N-acetyl-D-mannosamine 
transferase 
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 nagB   1/5 (1) 1/4 (1)   a  glucosamine-6-phosphate isomerase  
VAN  yycG       3/3 (2) a sensory box histidine kinase YycG 
*, Fraction of mutated lineages means how many lineages out of each experiment set contain mutations in a 
specific gene or site. The number in brackets means how many different mutation events were shared in total.  
** ,for example, in set RD2, 2 out of 4 lineages contain mutation in rpoB, while only 1 mutation event was 
found, i.e., all the mutations were the same. 
***, HP, hypothetical protein. 
# , mutational types: a, missense mutations; b, nonsense mutations; c, insertions and deletions (indels); d, large 
deletion(≈60kb);e, intergenic mutations. 
 
Table 6.  Number of genes with changed expression in evolved populations 
 Differently 
expressed  
Up 
regulated  
Down 
regulated  
Replicates 
of array 
samples 
Mutations 
RD14 57 39 18 2 relA-2 / GTP pyrophosphokinase (100%) 
RD11 21 11 10 3 SERP0014 / RND family efflux transporter, MFP component 
(75%) 
SERP0016 / ABC transporter, permease protein(25%); 
trkA / potassium uptake protein TrkA(83%) 
infB / translation initiation factor IF-2(99%) 
 
RD21 532 373 159 2 SERP0458 / sodium transport family protein (95%) 
RD31 371 239 63 3 rpoB / DNA-directed RNA polymerase, beta subunit (59%); 
yycG / sensory box histidine kinase YycG (45%) 
SERP1916//SERP1917 (40%);  
SERP0927 / amino acid carrier protein (57%) 
The number of genes with changed expression at least 2-fold in evolved populations (P≤0.05) 
Table 7. Genes up regulated in evolved resistant mutant RD14 or RD11 
Gene_ID Gene_NAME* RD14 RD11 Protein/Similarity 
SERP0014 
 
8.8  9.1  RND efflux transporter 
SERP0015 
 
12.4  13.6  ABC transporter, ATP-binding protein 
SERP0016 
 
11.2  10.9  ABC transporter, permease protein 
SERP0019 
 
4.0  hypothetical protein 
SERP0061 
 
3.4  3.4  2-keto-4-pentenoate hydratase, putative 
SERP0224 
 
3.0  3.4  hypothetical protein 
SERP0311 apsX 6.0  hypothetical protein 
SERP0312 apsR/graR 4.7  DNA-binding response regulator 
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SERP0313 apsS/graS 4.3  sensor histidine kinase 
SERP0314 vraF 3.2  ABC transporter, ATP-binding protein 
SERP0315 vraG 2.8  ABC transporter, permease protein 
SERP0663 
 
4.9  myosin-cross-reactive antigen 
SERP0915 
 
7.1  4.1  IS256-like transposase 
SERP0964 asd 2.9  aspartate-semialdehyde dehydrogenase 
SERP1271 pepQ 4.1  proline dipeptidase 
SERP1282 
 
2.5  GAF domain-containing protein 
SERP1286 
 
4.8  OsmC/Ohr family protein 
SERP1288 serA 4.5  D-3-phosphoglycerate dehydrogenase 
SERP2091 
 
6.8  hypothetical protein 
SERP2094 sdhA# 4.9  L-serine dehydratase, iron-sulfur-dependent, alpha subunit 
SERP2096 
 
4.3  perfringolysin O regulator protein, putative 
SERP2098 
 
5.5  hypothetical protein 
SERP2099 xylB 4.0  D-xylulose kinase 
SERP2102 
 
3.3  hypothetical protein 
SERP2103 dep 4.0  gamma-glutamyltranspeptidase 
SERP2105 capA 4.4  capA protein 
SERP2175 
 
6.1  amidohydrolase family protein 
SERP2176 betA# 
 
4.4  choline dehydrogenase 
SERP2212 
 
4.6  hypothetical protein 
SERP2279 
  
3.8  hypothetical protein 
SERP2295 icaB# 14.3  intercellular adhesion protein B 
SERP2469 
 
3.4  alcohol dehydrogenase, zinc-containing 
SERP2541 
 
3.6  homoserine O-acetyltransferase, putative 
*: The genes up regulated for no less than 2 fold are shown in this table.  
#: In the case of operons, only the first gene or the most strongly induced gene is shown.  
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Supplementary data  
Table S1. Full list of genes up regulated by AMP4d, AMP2b, VAN 
Gene_ID 
Gene_ 
NAME* 
4d 2b VAN PROTEIN 
SERP0019 
   
7.9 hypothetical protein 
SERP0020 
 
2.7 
  
ABC transporter, permease protein 
SERP0021 
 
2.9 4.4 19.8 ABC transporter, ATP-binding protein 
SERP0061 
    
2-keto-4-pentenoate hydratase, putative 
SERP0099 
 
4.7 3.5 
 
ABC transporter, substrate-binding protein 
SERP0109 gltD 5.5 2.9 
 
glutamate synthase subunit beta 
SERP0162 ctsR 7.8 4.4 
 
transcriptional regulator CtsR 
SERP0163 
 
7.2 7.4 3.0 UvrB/UvrC domain-containing protein 
SERP0164 
 
5.8 5.4 
 
ATP:guanido phosphotransferase 
SERP0165 clpC 5.2 3.7 
 
ATP-dependent Clp protease, ATP-binding subunit ClpC 
SERP0224 
 
5.3 3.4 3.5 hypothetical protein 
SERP0276 
 
3.1 2.9 
 
hypothetical protein 
SERP0281 
 
2.7 2.7 
 
putative monovalent cation/H+ antiporter subunit A 
SERP0282 
 
2.8 
  
putative monovalent cation/H+ antiporter subunit B 
SERP0288 
 
3.4 
  
hypothetical protein 
SERP0289 
 
3.6 3.4 
 
Na+/H+ antiporter, putative 
SERP0291 sitB 3.0 2.7 
 
ABC transporter, permease protein 
SERP0294 
 
3.9 3.2 5.9 hypothetical protein 
SERP0314 
 
2.7 3.0 
 
ABC transporter, ATP-binding protein 
SERP0315 
 
2.7 
  
ABC transporter, permease protein 
SERP0319 
 
2.9 
  
hypothetical protein 
SERP0339 uppP 2.6 2.7 2.9 undecaprenyl pyrophosphate phosphatase 
SERP0340 
  
3.0 
 
ABC transporter ATP-binding protein 
SERP0419 
 
7.2 2.9 
 
ribosomal subunit interface protein 
SERP0542 
 
2.9 
  
Oye family NADH-dependent flavin oxidoreductase 
SERP0551 
   
3.1 hypothetical protein 
SERP0564 clpB 10.4 9.0 
 
ATP-dependent Clp protease, ATP-binding subunit ClpB 
SERP0570 oppB 5.8 2.8 
 
oligopeptide ABC transporter, permease protein 
SERP0617 
 
6.9 4.0 
 
hypothetical protein 
SERP0620 
 
4.7 
  
hypothetical protein 
SERP0641 
 
2.8 
  
fmt protein 
SERP0742 
 
2.8 
  
hypothetical protein 
SERP0765 
  
2.5 
 
uracil permease 
SERP0883 
 
3.8 3.0 
 
hypothetical protein 
SERP0887 
 
4.7 7.7 
 
ABC transporter, permease protein 
SERP0888 
 
3.0 3.5 
 
sensor histidine kinase, putative 
SERP0889 
 
2.9 4.1 
 
LuxR family DNA-binding response regulator 
SERP0896 
 
3.7 
  
aspartate kinase 
SERP0897 hom 9.7 4.6 
 
homoserine dehydrogenase 
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SERP0898 thrC 9.5 4.7 
 
threonine synthase 
SERP0932 
   
2.9 transcriptional regulator, putative 
SERP0954 
 
2.3 2.2 2.9 hypothetical protein 
SERP0963 lysC 25.1 21.5 
 
aspartate kinase 
SERP0964 asd 22.6 17.6 
 
aspartate-semialdehyde dehydrogenase 
SERP0965 dapA 12.8 7.4 
 
dihydrodipicolinate synthase 
SERP0968 
 
12.0 7.1 
 
amidohydrolase family protein 
SERP0969 
 
7.5 6.8 
 
alanine racemase family protein 
lysA lysA 3.1 
  
diaminopimelate decarboxylase 
SERP0973 
  
3.0 3.4 hypothetical protein 
SERP0974 
 
2.7 3.6 3.1 acylphosphatase 
SERP0975 
 
3.0 2.8 
 
xpaC protein, putative 
SERP0996 
 
3.0 
  
carboxyl-terminal protease 
SERP1187 
 
3.2 2.4 
 
luciferase family protein 
SERP1215 
 
3.0 
 
2.6 hypothetical protein 
SERP1245 
  
2.7 
 
amino acid permease family protein 
SERP1292 
 
9.7 4.6 3.4 serine protease HtrA, putative 
SERP1376 prsA 3.5 3.1 2.9 protein export protein PrsA, putative 
vraR vraR 9.7 6.4 6.1 DNA-binding response regulator VraR 
vraS vraS 8.2 4.7 4.2 sensor histidine kinase VraS 
SERP1424 
 
10.1 6.8 6.7 hypothetical protein 
SERP1425 
 
5.5 
 
2.9 hypothetical protein 
SERP1667 
 
8.4 3.7 
 
acetolactate synthase 1 regulatory subunit 
SERP1668 ilvC 30.9 6.0 
 
ketol-acid reductoisomerase 
SERP1669 leuA 23.2 4.2 
 
2-isopropylmalate synthase 
SERP1701 
  
3.3 
 
TenA family transcription regulator 
SERP1790 lacE 2.7 
  
PTS system, lactose-specific IIBC components 
SERP1908 
 
4.1 2.8 4.1 hypothetical protein 
SERP2109 
 
2.7 
  
esterase, putative 
SERP2130 
 
2.9 
 
2.8 hypothetical protein 
SERP2131 
 
8.5 6.1 7.7 cation transporter E1-E2 family ATPase 
SERP2159 
 
4.0 3.7 
 
4-aminobutyrate aminotransferase 
SERP2176 betA 
  
4.0 choline dehydrogenase 
betB betB 
  
4.0 betaine aldehyde dehydrogenase 
gpxA-2 gpxA-2 3.0 
  
glutathione peroxidase 
SERP2195 
 
2.9 2.6 
 
alpha keto acid dehydrogenase complex, E3 component, 
lipoamide dehydrogenase, putative 
SERP2196 
 
3.2 
  
MarR family transcriptional regulator 
SERP2314 
 
3.2 
  
hypothetical protein 
SERP2327 
  
3.1 
 
acetoin dehydrogenase, E3 component, dihydrolipoamide 
dehydrogenase 
SERP2333 
  
3.0 
 
hypothetical protein 
SERP2345 
  
3.5 
 
dihydroxyacetone kinase subunit DhaK 
gldA gldA 
 
2.9 
 
glycerol dehydrogenase 
SERP2425 
 
3.3 3.1 
 
hypothetical protein 
SERP2426 
 
2.8 
  
ArsR family transcriptional regulator 
SERP2428 arsA 4.1 3.3 
 
arsenical pump-driving ATPase 
3 
 
SERP2469 
 
8.9 6.6 
 
alcohol dehydrogenase, zinc-containing 
SERP2541   4.2 5.1   homoserine O-acetyltransferase, putative 
*: The complete list of genes up regulated at least 2-fold by several antibiotics.  
**: 4d, 2b, VAN: RP62A exposed to sub-lethal concentration of AMP4d, AMP2b or VAN respectively.   
 
Table S2. Full list of genes down regulated by AMP4d, AMP2b, VAN 
 
Gene ID Gene Name* Down regulated with**  Protein/Similarity 
4d 2b VAN  
SERP0207 sdrG 3.1 2.8     
 
sdrG protein 
SERP0318   2.8 3.0      LysM domain-containing protein 
SERP1737 
 
3.8 2.4     
 
pantothenate kinase 
SERP1835 
 
4.5 2.8     
 
xanthine/uracil permease family protein 
SERP1880 
 
4.0 2.6     
 
secretory antigen precursor SsaA 
SERP2054 
 
3.4 2.3     
 
glycosyltransferase, group 1 family protein 
SERP2408 
 
21.3 10.3     
 
putative phospholipid methyltransferase 
SERP0190 
 
3.3       
 
amidohydrolase family protein 
SERP0505 
 
3.4       
 
hypothetical protein 
SERP0902 
 
3.3       
 
amino acid permease family protein 
SERP1421 
 
3.0       
 
ribonuclease BN, putative 
SERP1944 
 
3.0       
 
EmrB/QacA family drug resistance transporter 
SERP1945 
 
3.4       
 
drug transporter, putative 
SERP2034 
 
3.2       
 
amino acid permease family protein 
SERP2316 
 
3.1       
 
hypothetical protein 
SERP0081 
 
  3.2     
 
hypothetical protein 
SERP0776 gmk   3.0     
 
guanylate kinase 
SERP0364 saeS# 4.1 4.2 2.4   
 
sensor histidine kinase SaeS 
SERP0366 
 
4.9 6.3 3.3   
 
hypothetical protein 
SERP0367 5.1 5.9 3.8   putative lipoprotein 
SERP2127 
 
    3.3   
 
FeoA family protein 
SERP2149     3.7   hypothetical protein 
4 
 
SERP1972 
 
3.5 2.7   
  
AraC family transcriptional regulator 
SERP2161 
 
3.0     
  
putative lipoprotein 
*: List of genes induced at least 3-fold by several antibiotics. 
#: In the case of operons, only the first gene or the most strongly induced gene is shown. 
**: 4d, 2b, VAN: RP62A exposed to sub-lethal concentration of AMP4d, AMP2b or VAN respectively.   
 
Table S4. Genes down regulated in evolved resistant population RD14 and RD11 
PROTEIN_ID GENE_ID GENE_NAME RD14 RD11 Protein/Similarity 
YP_188319.1 SERP0736   5.3    phenol soluble modulin beta 1 
YP_188320.1 SERP0737   4.3    phenol soluble modulin beta 1 
YP_188321.1 SERP0738   5.3    phenol soluble modulin beta 1 
YP_188322.1 SERP0739   4.9    phenol soluble modulin beta 1 
YP_188448.1 glpF glpF 9.2    glycerol uptake facilitator protein 
YP_188449.1 glpK glpK 3.2    glycerol kinase 
YP_189055.1 hld hld 4.9    delta-hemolysin 
YP_189192.1 SERP1627     2.3  hypothetical protein 
YP_189411.1 sarV sarV 3.2    accessory regulator V 
YP_189430.1 ureA ureA 4.6  3.2  urease subunit gamma 
YP_189431.1 ureB ureB 4.0    urease subunit beta 
YP_189432.1 ureC ureC 4.0  2.6  urease subunit alpha 
YP_189433.1 ureE ureE 4.0  2.5  urease accessory protein UreE 
YP_189434.1 ureF ureF 4.6  3.2  urease accessory protein UreF 
YP_189509.1 SERP1951     3.0  ABC transporter, ATP-binding protein 
YP_189524.1 SERP1968   4.6    PTS system, sucrose-specific IIBC components 
YP_189528.1 SERP1972   3.5  3.2  AraC family transcriptional regulator 
YP_189717.1 SERP2161   3.2    putative lipoprotein 
YP_189847.1 geh-1 geh-1 3.7    lipase 
YP_189935.1 geh-2 geh-2 6.1  6.5  lipase 
YP_189962.1 SERP2417     4.0  putative lipoprotein 
 The complete list of genes down regulated at least 2-fold in RD14 and RD11.  
 
Table S5. Gene expression changes of RD21 and RD31 
Additional excel table. 
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Figure S1. Schematic diagram of resistant develop experiment design. 
 
Figure S1. 10 independent lineages of S.epidermidisRP62A were transferred in LB media with increasing 
concentrations of AMP4d, AMP2b, or VAN, respectively, for 40 transfers. In the end, 5, 4 or 3 resistant 
populations were evolved for SET_RD1 (developed from AMP4d), SET_RD2 (developed from AMP2b), or 
SET_RD 3 (developed from VAN), respectively. As controls, 3 independent lineages were transferred in LB 
media without antibiotics (SET_RD0).  
 
Figure S2. Overview of the selection experiments (linelage RD14, RD22, RD33 as examples). 
 
Figure S2. Overview of the selection experiment. No antibiotic was added to the LB media for the first transfer. 
From passage number 2, a non-inhibitory concentration of antibiotic of 0.5 μg/ml was used (MICs for RP62A 
with these antibiotics were 2 μg/ml). Then the concentrations were slowly increased. At some transfers such as 
transfer no. 9 for lineage RD14, the experiment was started from frozen culture sample.  
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Figure S3. Mutations and parallel evolution 
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Figure S3. Mutations and parallel evolution.  Mutation type: MS, Missense; NS, Nonsense; IN, Intergenic; IS, Insertion; DE, Deletion. 
The SNP call with with only 8% is in a population with THREE alleles (two mutations); Only RD24 have a 100% deletion(s) 
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Figure S4. S.epidermidis_nuc_pools (ppGpp study) 
 
 
Figure S5. S.epidermidis nuc pools-2D 
 
 
 
 
 
